T.RowePrice®



SEMIANNUAL REPORT

June 30, 2023

PRSVX	t. ROWE PRICE Small-Cap Value Fund
PASVX	Small-Cap Value Fund- Advisor Class
PRVIX	Small-Cap Value Fund- I Class
TRZVX	Small-Cap Value Fund- Z Class
	For more insights from T. Rowe Price investment professionals, go to
	troweprice.com.

Go Paperless

Sign up for e-delivery of your statements, confirmations, and prospectuses or shareholder reports.



(→) TO ENROLL:

If you invest directly with T. Rowe Price, go to troweprice.com/paperless.

If you invest through an investment advisor, a bank, or a brokerage firm, please contact that organization and ask if it can provide electronic documentation.

It's fast-receive your statements and confirmations faster than U.S. mail.

It's convenient-access your important account documents whenever you need them.

It's secure-we protect your online accounts using "True Identity" to confirm new accounts and make verification faster and more secure.

It can save you money—where applicable, T. Rowe Price passes on the cost savings to fund holders.*

Log in to your account at **troweprice.com** for more information.

*Certain mutual fund accounts that are assessed an annual account service fee can also save money by switching to e-delivery.

Market Commentary

Dear Shareholder

Most major global stock and bond indexes produced positive returns during the first half of your fund's fiscal year, the six-month period ended June 30, 2023. Despite turmoil in the banking sector and a protracted debt ceiling standoff, markets were resilient as growth remained positive in the major economies and corporate earnings results came in stronger than expected.

For the six-month period, the technology-oriented Nasdaq Composite Index gained more than 30%, the strongest result of the major benchmarks, as tech companies benefited from investor enthusiasm for artificial intelligence applications. Growth stocks outperformed value shares, and developed market stocks generally outpaced their emerging market counterparts. Currency movements were mixed over the period, although a weaker dollar versus major European currencies was beneficial for U.S. investors in European securities.

Within the S&P 500 Index, the information technology, communication services, and consumer discretionary sectors were all lifted by the tech rally and recorded significant gains. Conversely, the defensive utilities sector had the weakest returns in the growth-focused environment, and the energy sector also lost ground amid declining oil prices. The financials sector partly recovered from the failure of three large regional banks during the period but still finished with modest losses.

Cheaper oil contributed to slowing inflation, although core inflation readings—which exclude volatile food and energy prices—remained stubbornly high. In response, the Federal Reserve raised its short-term lending benchmark rate to a target range of 5.00% to 5.25% by early May, the highest level since 2007. The Fed held rates steady at its June meeting, but policymakers indicated that two more rate hikes could come by the end of the year.

In the fixed income market, returns were generally positive across most sectors as investors benefited from the higher interest rates that have become available over the past year. Investment-grade corporate bonds were supported by generally solid balance sheets and were among the strongest performers.

Global economies and markets showed surprising resilience in recent months, but, moving into the second half of 2023, we believe investors could face potential challenges. The impact of the Fed's rate hikes has yet to be fully felt in the economy, and while the regional banking turmoil appears to have been contained by the swift actions of regulators, it could weigh on credit conditions. Moreover, market consensus still seems to point to a coming recession, although hopes have emerged that such a downturn could be more modest.

We believe this environment makes skilled active management a critical tool for identifying risks and opportunities, and our investment teams will continue to use fundamental research to identify securities that can add value to your portfolio over the long term.

You may notice that this report no longer contains the commentary on your fund's performance and positioning that we previously included in the semiannual shareholder letters. The Securities and Exchange Commission (SEC) adopted new rules in January that will require fund reports to transition to a new format known as a Tailored Shareholder Report. This change will require a much more concise summary of performance rather than the level of detail we have provided historically while also aiming to be more visually engaging. As we prepare to make changes to the annual reports to meet the new report regulatory requirements by mid-2024, we felt the time was right to discontinue the optional six-month semiannual fund letter to focus on the changes to come.

While semiannual fund letters will no longer be produced, you may continue to access current fund information as well as insights and perspectives from our investment team on our personal investing website.

Thank you for your continued confidence in T. Rowe Price.

Sincerely,

Robert Sharps
CEO and President

Solut fr. Sharfa

Portfolio Summary

SECTOR DIVERSIFICATION

	Percent of Net Assets				
	12/31/22	6/30/23			
Financials	27.6%	24.6%			
Industrials and Business Services	14.3	14.5			
Health Care	11.7	11.2			
Consumer Discretionary	8.5	10.8			
Real Estate	9.0	9.9			
Energy	7.5	7.9			
Information Technology	5.5	5.9			
Utilities	5.2	4.9			
Materials	4.6	4.6			
Consumer Staples	3.3	2.9			
Communication Services	0.6	1.0			
Other and Reserves	2.2	1.8			
Total	100.0%	100.0%			

Historical weightings reflect current industry/sector classifications.

PORTFOLIO HIGHLIGHTS

TWENTY-FIVE LARGEST HOLDINGS

	Percent of Net Assets 6/30/23
Venture Global LNG	1.4%
Cava Group	1.3
Select Medical Holdings	1.2
IDACORP	1.1
Terreno Realty	1.1
UFP Industries	1.1
Littelfuse	1.1
Matador Resources	1.1
Beacon Roofing Supply	1.1
Meritage Homes	1.1
PennyMac Financial Services	1.0
TechnipFMC	1.0
Magnolia Oil & Gas	1.0
MGE Energy	1.0
Radian Group	0.9
Landstar System	0.9
SouthState	0.9
St. Joe	0.9
Pinnacle Financial Partners	0.8
EastGroup Properties	0.8
Constellium	0.8
Houlihan Lokey	0.8
Strategic Education	0.8
Popular	0.8
Columbia Banking System	0.8
Total	24.8%

Note: The information shown does not reflect any exchange-traded funds (ETFs), cash

reserves, or collateral for securities lending that may be held in the portfolio.

FUND EXPENSE EXAMPLE

As a mutual fund shareholder, you may incur two types of costs: (1) transaction costs, such as redemption fees or sales loads, and (2) ongoing costs, including management fees, distribution and service (12b-1) fees, and other fund expenses. The following example is intended to help you understand your ongoing costs (in dollars) of investing in the fund and to compare these costs with the ongoing costs of investing in other mutual funds. The example is based on an investment of \$1,000 invested at the beginning of the most recent six-month period and held for the entire period.

Please note that the fund has four share classes: The original share class (Investor Class) charges no distribution and service (12b-1) fee, Advisor Class shares are offered only through unaffiliated brokers and other financial intermediaries and charge a 0.25% 12b-1 fee, I Class shares are available to institutionally oriented clients and impose no 12b-1 or administrative fee payment, and Z Class shares are offered only to funds advised by T. Rowe Price and other advisory clients of T. Rowe Price or its affiliates that are subject to a contractual fee for investment management services and impose no 12b-1 fee or administrative fee payment. Each share class is presented separately in the table.

Actual Expenses

The first line of the following table (Actual) provides information about actual account values and expenses based on the fund's actual returns. You may use the information on this line, together with your account balance, to estimate the expenses that you paid over the period. Simply divide your account value by \$1,000 (for example, an \$8,600 account value divided by \$1,000 = 8.6), then multiply the result by the number on the first line under the heading "Expenses Paid During Period" to estimate the expenses you paid on your account during this period.

Hypothetical Example for Comparison Purposes

The information on the second line of the table (Hypothetical) is based on hypothetical account values and expenses derived from the fund's actual expense ratio and an assumed 5% per year rate of return before expenses (not the fund's actual return). You may compare the ongoing costs of investing in the fund with other funds by contrasting this 5% hypothetical example and the 5% hypothetical examples that appear in the shareholder reports of the other funds. The hypothetical account values and expenses may not be used to estimate the actual ending account balance or expenses you paid for the period.

Note: T. Rowe Price charges an annual account service fee of \$20, generally for accounts with less than \$10,000. The fee is waived for any investor whose T. Rowe Price mutual fund accounts total \$50,000 or more; accounts electing to receive electronic delivery of account statements, transaction confirmations, prospectuses, and shareholder reports; or accounts of an investor who is a T. Rowe Price Personal Services or Enhanced Personal Services client (enrollment in these programs generally requires T. Rowe Price assets of at least \$250,000). This fee is not included in the accompanying table. If you are subject to the fee, keep it in mind when you are estimating the ongoing expenses of investing in the fund and when comparing the expenses of this fund with other funds.

You should also be aware that the expenses shown in the table highlight only your ongoing costs and do not reflect any transaction costs, such as redemption fees or sales loads. Therefore, the second line of the table is useful in comparing ongoing costs only and will not help you determine the relative total costs of owning different funds. To the extent a fund charges transaction costs, however, the total cost of owning that fund is higher.

FUND EXPENSE EXAMPLE (CONTINUED)

SMALL-CAP VALUE FUND

	Beginning Account Value 1/1/23	Ending Account Value 6/30/23	Expenses Paid During Period* 1/1/23 to 6/30/23
Investor Class Actual	\$1,000.00	\$1,038.00	\$3.94
Hypothetical (assumes 5% return before expenses)	1,000.00	1,020.93	3.91
Advisor Class Actual	1,000.00	1,036.90	5.10
Hypothetical (assumes 5% return before expenses)	1,000.00	1,019.79	5.06
I Class Actual	1,000.00	1,038.70	3.39
Hypothetical (assumes 5% return before expenses)	1,000.00	1,021.47	3.36
Z Class Actual	1,000.00	1,042.10	0.00
Hypothetical (assumes 5% return before expenses)	1,000.00	1,024.79	0.00

^{*} Expenses are equal to the fund's annualized expense ratio for the 6-month period, multiplied by the average account value over the period, multiplied by the number of days in the most recent fiscal half year (181), and divided by the days in the year (365) to reflect the half-year period. The annualized expense ratio of the Investor Class was 0.78%, the Advisor Class was 1.01%, the I Class was 0.67%, and the Z Class was 0.00%.

FINANCIAL HIGHLIGHTS

For a share outstanding throughout each period

Investor Class						
	6 Months Ended 6/30/23	Year Ended 12/31/22	12/31/21	12/31/20	12/31/19	12/31/18
NET ASSET VALUE	0,00,20	, 0 .,	, 0 .,	, 0 ., _0	, 0 ., .0	, 0 ., .0
Beginning of period	\$ 47.90	\$ 61.79	\$ 52.79	\$ 47.91	\$ 39.85	\$ 49.06
Investment activities Net investment						
income ⁽¹⁾⁽²⁾ Net realized and	0.18	0.20	0.18	0.23	0.21	0.22
unrealized gain/loss	1.64	(11.56)	13.13	5.72	10.05	(5.66)
Total from investment activities	1.82	(11.36)	13.31	5.95	10.26	(5.44)
Distributions						
Net investment		(0.10)	(0.01)	(0.10)	(0.00)	(0.17)
income Net realized gain	_	(0.18) (2.35)	(0.21) (4.10)	(0.19) (0.88)	(0.29) (1.91)	(0.17) (3.60)
Total distributions	-	(2.53)	(4.31)	(0.00)	(2.20)	(3.77)
NET ASSET VALUE	\$ 49.72	\$ 47.90	\$ 61.79	\$ 52.79	\$ 47.91	\$ 39.85
End of period	φ 49.7Z	Ф 47.90	φ U1./9	φ 52.79	φ 4 7.91	დ აშ.00

FINANCIAL HIGHLIGHTS

For a share outstanding throughout each period

Investor Class

6 Months Year Ended Ended

6/30/23 12/31/22 12/31/21 12/31/20 12/31/19 12/31/18

Ratios/Supplemental Data

Total return ⁽²⁾⁽³⁾	3.80%	(18.55)%	25.54%	12.50%	25.84%	(11.49)%
Ratios to average net ass Gross expenses before waivers/ payments by Price	sets: ⁽²⁾					
Associates Net expenses after waivers/payments	0.78%(4)	0.79%	0.75%	0.76%	0.77%	0.78%
by Price Associates Net investment	0.78%(4)	0.79%	0.75%	0.76%	0.77%	0.78%
income	0.72%(4)	0.37%	0.29%	0.53%	0.45%	0.45%
Portfolio turnover rate Net assets, end of	13.9%	20.7%	25.1%	28.0%	22.3%	19.3%
period (in millions)	\$4,502	\$4,565	\$7,722	\$6,301	\$8,019	\$6,710

⁽¹⁾ Per share amounts calculated using average shares outstanding method.

The accompanying notes are an integral part of these financial statements.

⁽²⁾ See Note 6 for details of expense-related arrangements with Price Associates.

⁽³⁾ Total return reflects the rate that an investor would have earned on an investment in the fund during each period, assuming reinvestment of all distributions, and payment of no redemption or account fees, if applicable. Total return is not annualized for periods less than one year.

⁽⁴⁾ Annualized

FINANCIAL HIGHLIGHTS

For a share outstanding throughout each period

Advisor Class						
	6 Months Ended 6/30/23	Year Ended 12/31/22	12/31/21	12/31/20	12/31/19	12/31/18
NET ASSET VALUE	0,00,20	12/01/22	12/01/21	12/01/20	12/01/10	12/01/10
Beginning of period	\$ 47.76	\$ 61.60	\$ 52.64	\$ 47.80	\$ 39.75	\$ 48.81
Investment activities						
Net investment	0.10	0.00	(0.00)	0.11	0.07	0.00
income (loss) ⁽¹⁾⁽²⁾ Net realized and	0.12	0.02	(0.02)	0.11	0.07	0.09
unrealized gain/loss	1.64	(11.51)	13.08	5.66	10.02	(5.55)
Total from						
investment activities	1.76	(11.49)	13.06	5.77	10.09	(5.46)
Distributions						
Net investment						
income	_	_	_	(0.05)	(0.13)	_
Net realized gain	-	(2.35)	(4.10)	(0.88)	(1.91)	(3.60)
Total distributions	.	(2.35)	(4.10)	(0.93)	(2.04)	(3.60)
NET ACCET VALUE						
NET ASSET VALUE End of period	\$ 49.52	\$ 47.76	\$ 61.60	\$ 52.64	\$ 47.80	\$ 39.75
Life of period	Ψ -3.32	φ -1.70	φ 01.00	φ 32.04	φ +1.00	φ 59.75

FINANCIAL HIGHLIGHTS

For a share outstanding throughout each period

Advisor Class

6 Months Year Ended Ended

6/30/23 12/31/22 12/31/21 12/31/20 12/31/19 12/31/18

Ratios/Supplemental Data

Total return ⁽²⁾⁽³⁾	3.69%	(18.81)%	25.12%	12.14%	25.47%	(11.57)%
Ratios to average net ass Gross expenses before waivers/ payments by Price	sets: ⁽²⁾					
Associates Net expenses after waivers/payments	1.01%(4)	1.14%	1.08%	1.06%	1.08%	1.03%
by Price Associates Net investment	1.01%(4)	1.14%	1.08%	1.06%	1.08%	1.03%
income (loss)	0.50%(4)	0.03%	(0.04)%	0.25%	0.15%	0.18%
Portfolio turnover rate Net assets, end of	13.9%	20.7%	25.1%	28.0%	22.3%	19.3%
period (in millions)	\$77	\$77	\$105	\$97	\$105	\$108

⁽¹⁾ Per share amounts calculated using average shares outstanding method.

The accompanying notes are an integral part of these financial statements.

⁽²⁾ See Note 6 for details of expense-related arrangements with Price Associates.

⁽³⁾ Total return reflects the rate that an investor would have earned on an investment in the fund during each period, assuming reinvestment of all distributions, and payment of no redemption or account fees, if applicable. Total return is not annualized for periods less than one year.

⁽⁴⁾ Annualized

FINANCIAL HIGHLIGHTS

For a share outstanding throughout each period

I Class						
	6 Months Ended 6/30/23	Year Ended 12/31/22	12/31/21	12/31/20	12/31/19	12/31/18
NET ASSET VALUE	0/30/23	12/31/22	12/31/21	12/31/20	12/31/19	12/31/10
	\$ 47.80	\$ 61.72	\$ 52.76	\$ 47.89	\$ 39.84	\$ 49.06
Beginning of period	φ 47.00	\$ 61.72	φ 32.76	Ф 47.09	ф 39.04	φ 49.00
Investment activities Net investment						
income ⁽¹⁾⁽²⁾ Net realized and	0.20	0.28	0.25	0.27	0.26	0.28
unrealized gain/loss	1.65	(11.55)	13.12	5.72	10.05	(5.67)
Total from						
investment activities	1.85	(11.27)	13.37	5.99	10.31	(5.39)
Distributions Net investment						
income	_	(0.30)	(0.31)	(0.24)	(0.35)	(0.23)
Net realized gain	_	(2.35)	(4.10)	(0.88)	(1.91)	(3.60)
Total distributions	-	(2.65)	(4.41)	(1.12)	(2.26)	(3.83)
NET ASSET VALUE						
End of period	\$ 49.65	\$ 47.80	\$ 61.72	\$ 52.76	\$ 47.89	\$ 39.84

FINANCIAL HIGHLIGHTS

For a share outstanding throughout each period

I Class

6 Months Year Ended Ended 6/30/23 12/31/22 12/31/21 12/31/20 12/31/19 12/31/18

Ratios/Supplemental Data

Total return(2)(3)	3.87%	(18.43)%	25.67%	12.59%	25.97%	(11.40)%
Ratios to average net ass Gross expenses before waivers/ payments by Price	sets: ⁽²⁾					
Associates Net expenses after waivers/payments	0.67%(4)	0.67%	0.65%	0.66%	0.66%	0.66%
by Price Associates Net investment	0.67%(4)	0.67%	0.65%	0.66%	0.66%	0.66%
income	0.84%(4)	0.52%	0.40%	0.63%	0.56%	0.56%
Portfolio turnover rate Net assets, end of	13.9%	20.7%	25.1%	28.0%	22.3%	19.3%
period (in millions)	\$2,931	\$2,900	\$2,388	\$1,507	\$2,305	\$1,674

⁽¹⁾ Per share amounts calculated using average shares outstanding method.

The accompanying notes are an integral part of these financial statements.

⁽²⁾ See Note 6 for details of expense-related arrangements with Price Associates.

⁽³⁾ Total return reflects the rate that an investor would have earned on an investment in the fund during each period, assuming reinvestment of all distributions, and payment of no redemption or account fees, if applicable. Total return is not annualized for periods less than one year.

⁽⁴⁾ Annualized

FINANCIAL HIGHLIGHTS

For a share outstanding throughout each period

Z	C	a	SS
---	---	---	----

NET ASSET VALUE End of period	\$ 49.97	\$ 47.95	\$ 61.88	\$ 52.83
Net realized gain Total distributions		(2.35)	(4.10) (4.75)	(0.88) (1.34)
Distributions Net investment income	_	(0.62)	(0.65)	(0.46)
Net realized and unrealized gain/loss Total from investment activities	1.65 2.02	(11.59) (10.96)	13.16 13.80	23.08 23.51
Investment activities Net investment income ⁽²⁾⁽³⁾	0.37	0.63	0.64	0.43
NET ASSET VALUE Beginning of period	6 Months Ended 6/30/23 \$ 47.95	Year Ended 12/31/22 \$ 61.88	12/31/21 \$ 52.83	3/16/20 ⁽¹⁾ Through 12/31/20 \$ 30.66
		V		

Ratios/Supplemental Data	

Total return(3)(4)	4.21%	(17.90)%	26.48%	76.84%
Ratios to average net assets:(3)				
Gross expenses before waivers/payments by				
Price Associates	0.65%(5)	0.65%	0.64%	0.64%(5)
Net expenses after waivers/payments by Price				
Associates	0.00%(5)	0.00%	0.00%	0.00%(5)
Net investment income	1.51%(5)	1.17%	1.04%	1.26%(5)
Portfolio turnover rate	13.9%	20.7%	25.1%	28.0%
Net assets, end of period (in millions)	\$2,832	\$2,754	\$4,046	\$3,420

⁽¹⁾ Inception date

The accompanying notes are an integral part of these financial statements.

⁽²⁾ Per share amounts calculated using average shares outstanding method.

⁽³⁾ See Note 6 for details of expense-related arrangements with Price Associates.

⁽⁴⁾ Total return reflects the rate that an investor would have earned on an investment in the fund during each period, assuming reinvestment of all distributions, and payment of no redemption or account fees, if applicable. Total return is not annualized for periods less than one year.

⁽⁵⁾ Annualized

June 30, 2023 (Unaudited)

PORTFOLIO OF INVESTMENTS*	Shares/Par	\$ Value
(Cost and value in \$000s)		
COMMON STOCKS 94.9%		
COMMUNICATION SERVICES 0.9%		
Diversified Telecommunication Services 0.1%		
	700 500	10.005
Frontier Communications Parent (1) GCI Liberty, EC (2)	702,500 399,039	13,095
GOI LIDERTY, EO (Z)	399,039	10.005
Media 0.8%		13,095
Advantage Solutions (1)	6,269,623	14,671
Advantage Solutions, Warrants, 12/31/26, 11.50% (1)	400,000	52
Boston Omaha, Class A (1)	593,158	11,163
New York Times, Class A	1,246,700	49,095
Nexstar Media Group	60,000	9,993
Saga Communications, Class A	140,954	3,011
- Suga Communications, Olaco, t		87,985
Total Communication Services		101,080
CONSUMER DISCRETIONARY 10.8%		101,080
Automobile Components 1.2%		
Dorman Products (1)	616,833	48,625
LCI Industries	333,441	42,134
Strattec Security (1)(3)	334,806	6,093
Visteon (1)	175,046	25,138
		121,990
Broadline Retail 0.2%		
Kohl's	727,200	16,762
		16,762
Distributors 0.1%		
Pool Corp	29,363	11,001
· · · · · · · · · · · · · · · · · · ·		11,001
Diversified Consumer Services 0.9%		
Clear Secure, Class A (4)	387,443	8,977
Strategic Education	1,187,812	80,581
Grategio Education		89,558
Hotels, Restaurants & Leisure 3.1%		09,556
BJ's Restaurants (1)	686,837	21,841
Cava Group (1)	87,987	3,603
Cava Group, Acquisition Date: 6/23/20 - 3/26/21, Cost \$31,962 (1)		
(5)(6)	3,234,285	132,444
Deliveroo (GBP) (1)	14,166,784	20,621
Marriott Vacations Worldwide	358,356	43,978
Papa John's International	859,781	63,478
SeaWorld Entertainment (1)	87,900	4,923

	Shares/Par	\$ Value
(Cost and value in \$000s)		
Torchys Holdings, Class A, Acquisition Date: 11/13/20,		
Cost \$12,311 (1)(2)(5)(7)	1,439,856	7,804
Wyndham Hotels & Resorts	291,100	19,961
		318,653
Household Durables 1.3%		
Cavco Industries (1)	84,898	25,045
Meritage Homes	771.490	109,760
montage riomes		134,805
Leisure Products 0.2%		134,603
	0.000.000	15 110
Peloton Interactive, Class A (1)	2,008,200	15,443
Rad Power Bikes, Class A, Acquisition Date: 1/22/21, Cost \$5,494 (1)(2)(5)	1,138,910	683
0031 \(\psi_0, \pi 0 \pi \(1)(\pi)(0)	1,100,510	
Considire Batail 0.00/		16,126
Specialty Retail 2.8%		
Academy Sports & Outdoors	440,900	23,831
Asbury Automotive Group (1)	156,900	37,722
Caleres	1,241,700	29,714
Children's Place (1)(4) Farfetch, Class A (1)(4)	429,500 1,646,800	9,969
Floor & Decor Holdings, Class A (1)	149,700	15,563
Framebridge, EC, Acquisition Date: 5/19/20, Cost \$908 (1)(2)(5)	907,892	408
Group 1 Automotive	156,000	40,263
Hibbett	267,512	9,708
Monro	1,419,266	57,665
Petco Health & Wellness (1)(4)	2,981,937	26,539
Rent the Runway, Class A (1)(4)	2,977,865	5,896
RH (1)	27,900	9,195
Savers Value Village (1)	401,617	9,518
Winmark	8,168	2,716
		288,654
Textiles, Apparel & Luxury Goods 1.0%		
Bombas, Acquisition Date: 2/12/21, Cost \$14,601 (1)(2)(5)	3,303,766	11,596
Canada Goose Holdings (1)(4)	512,300	9,119
Figs, Class A (1)	4,452,917	36,826
Steven Madden	1,450,140	47,405
		104,946
Total Consumer Discretionary		1,102,495
CONSUMER STAPLES 2.3%		1,102,433
Beverages 0.6%		
-	14 266	A A01
Boston Beer, Class A (1) Coca-Cola Consolidated	14,366 90,474	4,431
Oud-Ouid Outisulluated	30,474	57,543
		61,974

	Shares/Par	\$ Value
(Cost and value in \$000s)		
Consumer Staples Distribution & Retail 0.1%		
Sprouts Farmers Market (1)	291,700	10,714
		10,714
Food Products 1.4%		
Nomad Foods (1)	3,660,700	64,135
Post Holdings (1)	531,830	46,083
Simply Good Foods (1)	1,052,581	38,514
Household Products 0.2%		148,732
Reynolds Consumer Products	742,500	20,976
		20,976
Total Consumer Staples		242,396
ENERGY 7.9%		
Energy Equipment & Services 3.7%		
Cactus, Class A	1,234,479	52,243
ChampionX	2,236,262	69,414
Enerflex (CAD)	7,078,229	48,194
Energy Reservoir Holdings, Class A-1, Acquisition Date: 4/30/19,	00 074 544	0.000
Cost \$20,875 (1)(2)(3)(5)(7) Expro Group Holdings (1)	20,874,541 2,460,609	9,393
Liberty Energy, Class A	2,485,099	33,226
Ranger Energy Services (1)(3)	1,693,860	17,345
TechnipFMC (1)	6,449,993	107,199
		380,616
Oil, Gas & Consumable Fuels 4.2%		
Advantage Energy (CAD) (1)(4)	4,277,547	27,930
International Seaways	247,272	9,456
Magnolia Oil & Gas, Class A	4,994,370	104,382
Matador Resources	2,145,051	112,229
Range Resources	1,083,500	31,855
REX American Resources (1)	311,971	10,860
Venture Global LNG, Series B, Acquisition Date: 3/8/18,	105	7 020
Cost \$1,314 (1)(2)(5)	435	7,830
Venture Global LNG, Series C, Acquisition Date: 5/25/17 - 3/8/18, Cost \$26,302 (1)(2)(5)	7,197	129,546
		434,088
Total Energy		814,704
FINANCIALS 24.2%		
Banks 14.8%		
BankUnited	3,307,658	71,280
Blue Foundry Bancorp (1)(4)	897,252	9,071
Burke & Herbert Financial Services	39,344	2,526

	Shares/Par	\$ Value
(Cost and value in \$000s)		
Cathay General Bancorp	636,100	20,476
Coastal Financial (1)	563,616	21.220
Columbia Banking System	3,907,062	79,235
Columbia Financial (1)(4)	1,063,310	18.385
CRB Group, Acquisition Date: 4/14/22, Cost \$3,215 (1)(2)(5)	30,579	2,365
CrossFirst Bankshares (1)	2,046,105	20,461
Dogwood State Bank, Non-Voting Shares, Acquisition Date:		
5/6/19, Cost \$2,923 (1)(2)(3)(5)	292,336	5,847
Dogwood State Bank, Voting Shares, Acquisition Date: 5/6/19,		
Cost \$1,436 (1)(2)(3)(5)	143,582	2,872
Dogwood State Bank, Warrants, 5/6/24, Acquisition Date: 5/6/19,		
Cost \$- (1)(2)(3)(5)	43,592	454
East West Bancorp	1,149,275	60,670
Eastern Bankshares	6,027,108	73,953
Farmers & Merchants Bank of Long Beach	2,471	13,430
FB Financial	1,526,123	42,808
First Bancshares (4)	701,081	18,116
FS Bancorp (3)	670,758	20,170
Grasshopper Bancorp, Acquisition Date: 10/12/18 - 5/2/19,		
Cost \$5,034 (1)(2)(5)	503,404	1,213
Grasshopper Bancorp, Warrants, 10/12/28, Acquisition Date:		
10/12/18, Cost \$— (1)(2)(5)	100,220	16
HarborOne Bancorp	2,728,073	23,680
Home BancShares	3,457,051	78,821
Independent Bank	505,895	22,517
Independent Bank Group	827,512	28,574
John Marshall Bancorp (3)(4)	1,057,188	21,239
Kearny Financial	2,520,255	17,768
Live Oak Bancshares (3)	2,482,836	65,323
Metropolitan Bank Holding (1)(3)(4)	556,623	19,331
National Bank Holdings, Class A (3)	1,957,165	56,836
Origin Bancorp	903,349	26,468
Pacific Premier Bancorp	1,189,273	24,594
Pinnacle Financial Partners	1,522,634	86,257
Ponce Financial Group (1)(4)	1,771,577	15,395
Popular	1,318,136	79,773
Preferred Bank (3)	920,209	50,602
Provident Bancorp	1,180,107	9,771
Sandy Spring Bancorp	1,574,237	35,704
Southern First Bancshares (1)(3)	454,722	11,254
SouthState	1,373,537	90,379
Texas Capital Bancshares (1)	1,140,538	58,738
Towne Bank	2,436,352	56,621
Veritex Holdings	1,215,490	21,794
Webster Financial	954,987	36,051
Western Alliance Bancorp	1,121,707	40,909
11000117 illiando bandorp	1,121,101	

	Shares/Par	\$ Value
(Cost and value in \$000s)		
WSFS Financial	1,685,128	63,563
		1,526,530
Capital Markets 2.2%		
AssetMark Financial Holdings (1)	1,346,684	39,943
Houlihan Lokey	836,023	82,189
Main Street Capital (4)	325,732	13,039
OTC Markets Group, Class A	411,454	23,700
StepStone Group, Class A	647,975	16,076
Virtus Investment Partners	268,652	53,051
		227,998
Consumer Finance 1.1%		
Green Dot, Class A (1)	2,440,998	45,744
NerdWallet, Class A (1)	1,224,278	11,521
PRA Group (1)	821,298	18,767
PROG Holdings (1)	1,337,184	42,950
Financial Comings 0.00/		118,982
Financial Services 2.8%	1 000 117	10.570
Conyers Park III Acquisition (1)	1,328,447	13,576
PennyMac Financial Services	1,529,894	107,567
Radian Group	3,776,176	95,462
Stash Financial, Acquisition Date: 1/6/21 - 1/26/21,	38,630	563
Cost \$1,244 (1)(2)(5) Voya Financial	307,900	22,079
Walker & Dunlop	679,160	53,715
waiter & Duniop	079,100	292,962
Insurance 2.1%		292,902
BRP Group, Class A (1)	992,026	24,582
Coalition, Acquisition Date: 9/13/21, Cost \$357 (1)(2)(5)	21,587	364
First American Financial	182.400	10.400
Hagerty, Warrants, 12/1/26, 11.50% (1)	257,272	541
James River Group Holdings (3)	2,279,810	41,629
Palomar Holdings (1)	180,486	10,475
ProAssurance	2,499,327	37,715
Ryan Specialty Holdings, Class A (1)	1,179,028	52,927
Selective Insurance Group	232,726	22,330
Skyward Specialty Insurance Group (1)	294,796	7,488
White Mountains Insurance Group	2,802	3,892
		212,343
Mortgage Real Estate Investment Trusts 1.2%		
Hannon Armstrong Sustainable Infrastructure Capital, REIT (4)	3,065,595	76,640
PennyMac Mortgage Investment Trust, REIT	3,739,672	50,411
		127,051
Total Financials		2,505,866

### HEALTH CARE 10.4% Biotechnology 4.5% Apellis Pharmaceuticals (1) 495,125 45,106 Ascendis Pharma, ADR (1) 276,800 24,704 Biueprint Medicines (1) 506,432 32,006 Cerevel Therapeutics Holdings (1) 461,165 14,660 CRISPR Therapeutics (1)(4) 317,300 17,813 Denail Therapeutics (1)(1) 330,500 10,781 Denail Therapeutics (1) 440,038 12,986 Generation Bio (1) 798,408 4,391 HilleVax (1) 348,562 5,992 Icosavax (1) 1,585,455 15,744 Immatics (1) 426,137 4,918 Insmed (1) 1,967,929 41,523 Ionis Pharmaceuticals (1) 907,800 37,247 Karuna Therapeutics (1) 179,930 39,018 Kymera Therapeutics (1) 179,930 39,018 Kymera Therapeutics (1) 1,806,000 9,662 Monte Rosa Therapeutics (1)(4) 13,580 93 MoonLake Immunotherapeutics (1) 14,700 6,576 Morpho Holding (1) 1,554,800 11,614 Nkarta (1)(4) 1,554,800 11,614 Nkarta (1)(4) 1,554,800 11,614 Nkarta (1)(4) 1,554,800 11,614 Nkarta (1)(4) 1,806,001 9,662 Morpher Holding (1) 1,967,929 11,574 Replamen (1) 1,554,800 11,614 Nkarta (1)(4) 1,806,001 9,662 Morpher Holding (1) 1,967,929 11,574 Syndax Pharpaceutics (1)(4) 80,713 Replamen (1) 1,554,800 11,614 Nkarta (1)(4) 1,806,001 1,967,903 Forthena (1) 1,967,903 7,648 Replimune Group (1) 498,429 11,574 Syndax Pharmaceuticals (1)(4) 883,580 5,187 Replamen Group (1) 498,429 11,574 Syndax Pharmaceuticals (1)(4) 883,580 5,187 Health Care Equipment & Supplies 2.2% Atrion (4) 68,517 38,760 Avanos Medical (1) 598,419 50,219 Pax Labs, Class A, Acquisition Date: 4/18/19, Cost \$9,910 (1)(2) (5) (2,631,808 12,63) Utah Medical Products (3) 235,955 21,991		Shares/Par	\$ Value
Apellis Pharmaceuticals (1)	(Cost and value in \$000s)		
Apellis Pharmaceuticals (1) 495,125 45,106 Ascendis Pharma, ADR (1) 276,800 24,704 Blueprint Medicines (1) 506,432 32,006 Cerevel Therapeutics Holdings (1) 461,165 14,666 CRISPR Therapeutics (1)(4) 317,300 17,813 Cytokinetics (1) 330,500 10,781 Denall Therapeutics (1) 440,038 12,986 Generation Bio (1) 798,408 4,391 HilleVax (1) 348,562 5,992 Loosavax (1) 1,585,455 15,744 Immatics (1) 1,967,929 41,523 lonis Pharmaceuticals (1) 907,800 37,247 Karuna Therapeutics (1) 907,800 37,247 Karuna Therapeutics (1) 179,930 39,018 MacroGenics (1)(4) 1,806,000 9,662 Monte Rosa Therapeutics (1) 1,186,000 9,662 Monte Rosa Therapeutics (1) 1,14,700 6,576 Morphic Holding (1) 1,554,800 11,614 Nkarta (1)(4) 1,645,141 3,600 Morphic Holding (1) 1,057,939 7,648 Replimune Group (1) 1,967,939 7,648 Replimune Group (1) 498,429 31,577 Relay Therapeutics (1)(4) 883,580 5,187 Verve Therapeutics (1)(4) 514,029 9,638 Tenaya Therapeutics (1)(4) 883,580 5,187 Verve Therapeutics (1)(4) 514,029 9,638 Tenaya Therapeutics (1)(4) 514,029 9,638 Ten	HEALTH CARE 10.4%		
Ascendis Pharma, ADR (1) 276,800 24,704 Blueprint Medicines (1) 506,432 32,006 Cerevel Therapeutics Holdings (1) 481,165 14,660 CRISPR Therapeutics (1)(4) 317,300 17,813 Cytokinetics (1) 330,500 10,781 Denall Therapeutics (1) 440,038 12,986 Generation Bio (1) 798,408 4,391 HilleVax (1) 348,562 5,992 Lossavax (1) 1,585,455 15,744 Immatics (1) 1,967,929 41,523 Ionis Pharmaceuticals (1) 907,800 37,247 Karuna Therapeutics (1) 190,7800 37,247 Karuna Therapeutics (1) 179,930 39,018 Wymera Therapeutics (1) 179,930 39,018 MacroGenics (1)(4) 1,866,000 9,662 Monte Rosa Therapeutics (1) 1,868,465 9,230 MoonLake Immunotherapeutics (1) 1,868,465 9,230 Morphic Holding (1) 1,470 6,576 MorphoSys, ADR (1) 1,554,800 11,614 Nkarta (1)(4) 1,645,141 3,603 Trothena (1) 1,645,141 3,603 Trothena (1) 1,645,141 3,603 Trothena (1) 809,713 10,170 Repare Therapeutics (1)(4) 809,713 10,170 Repare Therapeutics (1)(4) 83,560 13,488 Tenaya Therapeutics (1)(4) 883,560 5,187 Verve Thera	Biotechnology 4.5%		
Blueprint Medicines (1) 506,432 32,006 Cerevel Therapeutics Holdings (1) 461,165 14,660 CRISPR Therapeutics (1)(4) 317,300 17,813 Cytokinetics (1) 330,500 10,781 Denall Therapeutics (1) 440,038 12,986 Generation Bio (1) 798,408 4,391 HilleVax (1) 348,562 5,992 Icosavax (1) 1,585,455 15,744 Immatics (1) 426,137 4,918 Insmed (1) 1,967,929 41,523 Ionis Pharmaceuticals (1) 907,800 37,247 Karuna Therapeutics (1) 179,930 39,018 Kymera Therapeutics (1) 179,930 39,018 Kymera Therapeutics (1) 1,806,000 9,662 Monte Rosa Therapeutics (1)(4) 1,3580 99 MoonLake Immunotherapeutics (1) 1,14,700 6,576 Morphic Holding (1) 1,554,800 11,614 Nkarta (1)(4) 1,645,141 3,603 Prothena (1) 1,554,800 11,614 Prothena (1) 1,645,141 3,603 Prothena (1) 1,645,141 3,603 Prothena (1) 1,548,00 1,167 Repaire Therapeutics (1)(4) 89,713 10,170 Relay Therapeutics (1)(4) 883,580 5,187 Syndax Pharmaceuticals (1) 421,685 11,896 Xenor (1) 488,429 11,574 Syndax Pharmaceuticals (1)(4) 883,580 5,187 Verve Therapeutics (1)(4) 883,580 5,1	Apellis Pharmaceuticals (1)	495,125	45,106
Cerevel Therapeutics Holdings (1) 461,165 14,660 CRISPR Therapeutics (1)(4) 317,300 17,813 Cytokinetics (1) 330,500 10,781 Denall Therapeutics (1) 440,038 12,986 Generation Bio (1) 798,408 4,391 HilleVax (1) 348,562 5,992 Losavax (1) 1,585,455 15,744 Immatics (1) 426,137 4,918 Insmed (1) 1,967,929 41,523 Ionis Pharmaceuticals (1) 907,800 37,247 Karuna Therapeutics (1) 179,930 39,018 Kymera Therapeutics (1) 634,953 14,598 MacroGenics (1)(4) 1,806,000 9,662 Monte Rosa Therapeutics (1)(4) 1,806,000 9,662 Morphic Holding (1) 114,700 6,576 Morphic Holding (1) 114,700 6,576 MorphoSys, ADR (1) 1,554,800 11,614 Nkarta (1)(4) 1,655,141 3,600 Nkarta (1)(4) 1,645,141 3,603 Replair Therapeutics (Ascendis Pharma, ADR (1)	276,800	24,704
CRISPR Therapeutics (1)(4) 317,300 17,813 Cytokinetics (1) 330,500 10,781 Denali Therapeutics (1) 440,038 12,986 Generation Bio (1) 798,408 4,391 HilleVax (1) 348,562 5,992 Lossavax (1) 1,585,455 15,744 Immatics (1) 426,137 4,918 Insmed (1) 1,967,929 41,523 Ionis Pharmaceuticals (1) 907,800 37,247 Karuna Therapeutics (1) 179,930 39,018 Kymera Therapeutics (1) 179,930 39,018 Kymera Therapeutics (1) 1,806,000 9,662 Monte Rosa Therapeutics (1) 1,806,000 9,662 Monte Rosa Therapeutics (1) 1,806,000 9,662 Morphic Holding (1) 1,154,800 11,614 Nkarta (1)(4) 1,554,800 11,614 Nkarta (1)(4) 1,554,800 11,614 Nkarta (1)(4) 1,645,141 3,603 Prothena (1) 1,05,013 7,170 Relay Therapeutics (1)(4) 809,713 10,170 Repare Therapeutics (1)(4) 809,713 10,170 Repare Therapeutics (1)(4) 883,580 5,187 Verve Therapeutics (1)(4) 9,638 Xencor (1) 1,198,858 29,935 Zentalis Pharmaceuticals (1) 68,517 38,760 Avanos Medical (1) 940,800 24,047 Embecta 1,351,608 29,195 Lantheus Holdings (1) 598,419 50,218 Pax Labs, Class A, Acquisition Date: 4/18/19, Cost \$9,910 (1)(2) (5) 2,631,808 1,263 QuidelOrtho (1) 699,768 57,983 Utah Medical Products (3) 235,955 21,991	Blueprint Medicines (1)	506,432	32,006
Cytokinetics (1) 330,500 10,781 Denali Therapeutics (1) 440,038 12,986 Generation Bio (1) 798,408 4,391 HillleVax (1) 348,562 5,992 Icosavax (1) 1,585,455 15,744 Immatics (1) 426,137 4,918 Insmed (1) 1,967,929 41,523 Ionis Pharmaceuticals (1) 907,800 37,247 Karuna Therapeutics (1) 179,930 39,018 Kymera Therapeutics (1) 634,953 14,598 MacroGenics (1)(4) 1,806,000 9,662 Monte Rosa Therapeutics (1)(4) 13,580 93 MoorLake Immunotherapeutics (1) 180,986 9,233 Morphic Holding (1) 114,700 6,576 Morphic Holding (1) 1,645,141 3,603 Prothena (1) 1,554,800 11,614 Nkarta (1)(4) 1,645,141 3,603 Prothena (1) 105,013 7,170 Repaire Therapeutics (1)(4) 722,939 7,649 Replimune Group (1) 498,429 11,574 Syndax Pharmaceuticals (1)(4) <t< td=""><td>Cerevel Therapeutics Holdings (1)</td><td>461,165</td><td>14,660</td></t<>	Cerevel Therapeutics Holdings (1)	461,165	14,660
Denail Therapeutics (1) 440,038 12,986 Generation Bio (1) 798,408 4,391 HilleVax (1) 348,562 5,992 Icosavax (1) 1,585,455 15,744 Immatics (1) 426,137 4,918 Insmed (1) 1,967,929 41,523 Ionis Pharmaceuticals (1) 907,800 37,247 Karuna Therapeutics (1) 634,953 14,598 MacroGenics (1)(4) 1,806,000 9,662 Monte Rosa Therapeutics (1)(4) 13,580 93 Morphic Holding (1) 114,700 6,576 Morphic Holding (1) 114,700 6,576 Morphic Holding (1) 1,645,141 3,603 Myrophic Holding (1) 1,554,800 11,614 Nkarta (1)(4) 1,645,141 3,603 Prothena (1) 105,013 7,770 Relay Therapeutics (1)(4) 722,939 7,648 Replimune Group (1) 498,429 11,574 Syndax Pharmaceuticals (1)(4) 883,580 13,489 Tenaya Therapeutics (1)(4)	CRISPR Therapeutics (1)(4)	317,300	17,813
Generation Bio (1) 798,408 4,391 HilleVax (1) 348,562 5,992 Icosavax (1) 1,585,555 15,744 Immatics (1) 426,137 4,918 Insmed (1) 1,967,929 41,523 Ionis Pharmaceuticals (1) 907,800 37,247 Karuna Therapeutics (1) 179,930 39,018 Kymera Therapeutics (1) 634,953 14,598 Morphocologics (1)(4) 13,580 93 Monte Rosa Therapeutics (1)(4) 13,580 93 Morphocologic (1)(4) 13,580 93 Morphic Holding (1) 114,700 6,576 Morphocologic (1) 114,700 6,576 Morphocologic (1) 1,645,141 3,603 Morphic Holding (1) 1,645,141 3,603 Morphic Holding (1) 105,013 7,170 Morphocologic (1) 809,713 10,170 Repair Therapeutics (1) 809,713 10,170 Repair Therapeutics (1)(4) 722,939 7,649 Replimune Group (1) 498,429 11,574 Syndax Pharmaceuticals (1) 644,500	Cytokinetics (1)	330,500	10,781
HilleVax (1) 348,562 5,992 lcosavax (1) 1,585,455 15,744 lmmatics (1) 426,137 4,918	Denali Therapeutics (1)	440,038	12,986
Icosavax (1) 1,585,455 15,744 Immatics (1) 426,137 4,918 Insmed (1) 1,967,929 41,523 Ionis Pharmaceuticals (1) 907,800 37,247 Karuna Therapeutics (1) 179,930 39,018 Kymera Therapeutics (1) 634,953 14,598 MacroGenics (1)(4) 1,806,000 9,662 Montal Rosa Therapeutics (1)(4) 13,580 93 MoonLake Immunotherapeutics (1) 180,986 9,230 Morphic Holding (1) 114,700 6,576 Morphic Holding (1) 1,554,800 11,614 Nkarta (1)(4) 1,645,141 3,603 Prothena (1) 105,013 7,170 Relay Therapeutics (1) 809,713 10,170 Repair Therapeutics (1)(4) 722,939 7,648 Replimune Group (1) 498,429 11,574 Syndax Pharmaceuticals (1) 644,500 13,489 Tenaya Therapeutics (1)(4) 883,580 5,187 Verve Therapeutics (1)(4) 883,580 5,187 V	Generation Bio (1)	798,408	4,391
Immatics (1) 426,137 4,918 Insmed (1) 1,967,929 41,523 Ionis Pharmaceuticals (1) 907,800 37,247 Karuna Therapeutics (1) 179,930 39,018 Kymera Therapeutics (1) 634,953 14,598 MacroGenics (1)(4) 1,806,000 9,662 Monte Rosa Therapeutics (1)(4) 13,580 93 Morphic Holding (1) 180,986 9,230 Morphic Holding (1) 114,700 6,576 MorphoSys, ADR (1) 1,554,800 11,614 Nkarta (1)(4) 1,645,141 3,603 Prothena (1) 105,013 7,170 Relay Therapeutics (1) 809,713 10,170 Repare Therapeutics (1)(4) 722,939 7,649 Replimune Group (1) 498,429 11,574 Syndax Pharmaceuticals (1) 644,500 13,489 Verve Therapeutics (1)(4) 883,580 5,187 Verve Therapeutics (1)(4) 514,029 9,638 Xencor (1) 1,198,858 29,935 Zentalis Pharmaceuticals (1)(4) 421,685 11,896 Avanos Medica	HilleVax (1)	348,562	5,992
Immatics (1) 426,137 4,918 Insmed (1) 1,967,929 41,523 Ionis Pharmaceuticals (1) 907,800 37,247 Karuna Therapeutics (1) 179,930 39,018 Kymera Therapeutics (1) 634,953 14,598 MacroGenics (1)(4) 1,806,000 9,662 Monte Rosa Therapeutics (1)(4) 13,580 93 Morphic Holding (1) 180,986 9,230 Morphic Holding (1) 114,700 6,576 MorphoSys, ADR (1) 1,554,800 11,614 Nkarta (1)(4) 1,645,141 3,603 Prothena (1) 105,013 7,170 Relay Therapeutics (1) 809,713 10,170 Repare Therapeutics (1)(4) 722,939 7,649 Replimune Group (1) 498,429 11,574 Syndax Pharmaceuticals (1) 644,500 13,489 Verve Therapeutics (1)(4) 883,580 5,187 Verve Therapeutics (1)(4) 514,029 9,638 Xencor (1) 1,198,858 29,935 Zentalis Pharmaceuticals (1)(4) 421,685 11,896 Avanos Medica	Icosavax (1)	1,585,455	15,744
Insmed (1) 1,967,929 41,523 Ionis Pharmaceuticals (1) 907,800 37,247 Karuna Therapeutics (1) 179,930 39,018 Kymera Therapeutics (1) 634,953 14,598 MacroGenics (1)(4) 1,806,000 9,662 Monte Rosa Therapeutics (1) 180,986 9,230 Morphic Holding (1) 114,700 6,576 MorphoSys, ADR (1) 1,554,800 11,614 Nkarta (1)(4) 1,645,141 3,603 Prothena (1) 105,013 7,170 Relay Therapeutics (1) 809,713 10,170 Repaire Therapeutics (1)(4) 722,939 7,649 Replimune Group (1) 498,429 11,574 Syndax Pharmaceuticals (1)(4) 883,580 5,187 Verve Therapeutics (1)(4) 883,580 5,187 Verve Therapeutics (1)(4) 514,029 9,638 Xencor (1) 1,198,858 29,935 Zentalis Pharmaceuticals (1)(4) 421,685 11,896 Avanos Medical (1) 940,800 24,047 Embecta 1,351,608 29,195 Lantheus Ho		426,137	4,918
Karuna Therapeutics (1) 179,930 39,018 Kymera Therapeutics (1) 634,953 14,598 MacroGenics (1)(4) 1,806,000 9,662 Monte Rosa Therapeutics (1)(4) 13,580 93 MoonLake Immunotherapeutics (1) 180,986 9,230 Morphic Holding (1) 114,700 6,576 MorphoSys, ADR (1) 1,554,800 11,614 Nkarta (1)(4) 1,645,141 3,603 Prothena (1) 105,013 7,170 Relay Therapeutics (1) 809,713 10,170 Replay Therapeutics (1)(4) 722,939 7,649 Replimune Group (1) 498,429 11,574 Syndax Pharmaceuticals (1) 644,500 13,488 Tenaya Therapeutics (1)(4) 883,580 5,187 Verve Therapeutics (1)(4) 883,580 5,187 Verve Therapeutics (1)(4) 421,685 11,896 Xencor (1) 1,198,858 29,935 Zentalis Pharmaceuticals (1)(4) 421,685 11,896 Avanos Medical (1) 940,800 24,047 Embecta 1,351,608 29,195		1,967,929	41,523
Kymera Therapeutics (1) (4) 634,953 14,598 MacroGenics (1)(4) 1,806,000 9,662 Monte Rosa Therapeutics (1)(4) 13,580 93 MoonLake Immunotherapeutics (1) 180,986 9,230 Morphic Holding (1) 114,700 6,576 MorphoSys, ADR (1) 1,554,800 11,611 Nkarta (1)(4) 1,645,141 3,603 Prothena (1) 105,013 7,170 Relay Therapeutics (1) 809,713 10,170 Repare Therapeutics (1)(4) 722,939 7,649 Replimune Group (1) 498,429 11,574 Syndax Pharmaceuticals (1) 644,500 13,488 Tenaya Therapeutics (1)(4) 883,580 5,187 Verve Therapeutics (1)(4) 883,580 5,187 Verve Therapeutics (1)(4) 514,029 9,638 Xencor (1) 1,198,858 29,935 Zentalis Pharmaceuticals (1)(4) 421,685 11,896 Health Care Equipment & Supplies 2.2% Atrion (4) 68,517 38,760 Avanos Medical (1) 940,800 24,047 Embecta 1,351,608	Ionis Pharmaceuticals (1)	907,800	37,247
Kymera Therapeutics (1) (4) 634,953 14,598 MacroGenics (1)(4) 1,806,000 9,662 Monte Rosa Therapeutics (1)(4) 13,580 93 MoonLake Immunotherapeutics (1) 180,986 9,230 Morphic Holding (1) 114,700 6,576 MorphoSys, ADR (1) 1,554,800 11,611 Nkarta (1)(4) 1,645,141 3,603 Prothena (1) 105,013 7,170 Relay Therapeutics (1) 809,713 10,170 Repare Therapeutics (1)(4) 722,939 7,649 Replimune Group (1) 498,429 11,574 Syndax Pharmaceuticals (1) 644,500 13,488 Tenaya Therapeutics (1)(4) 883,580 5,187 Verve Therapeutics (1)(4) 883,580 5,187 Verve Therapeutics (1)(4) 514,029 9,638 Xencor (1) 1,198,858 29,935 Zentalis Pharmaceuticals (1)(4) 421,685 11,896 Health Care Equipment & Supplies 2.2% Atrion (4) 68,517 38,760 Avanos Medical (1) 940,800 24,047 Embecta 1,351,608	Karuna Therapeutics (1)	179,930	39,018
MacroGenics (1)(4) 1,806,000 9,662 Monte Rosa Therapeutics (1)(4) 13,580 93 MoonLake Immunotherapeutics (1) 180,986 9,230 Morphic Holding (1) 114,700 6,576 MorphoSys, ADR (1) 1,554,800 11,614 Nkarta (1)(4) 1,645,141 3,603 Prothena (1) 105,013 7,170 Relay Therapeutics (1) 809,713 10,170 Repaire Therapeutics (1)(4) 722,939 7,649 Replimune Group (1) 498,429 11,574 Syndax Pharmaceuticals (1) 644,500 13,488 Tenaya Therapeutics (1)(4) 883,580 5,187 Verve Therapeutics (1)(4) 514,029 9,638 Xencor (1) 1,198,858 29,935 Zentalis Pharmaceuticals (1)(4) 421,685 11,896 Health Care Equipment & Supplies 2.2% Atrion (4) 68,517 38,760 Avanos Medical (1) 940,800 24,047 Embecta 1,351,608 29,195 Lantheus Holdings (1) 598,419 50,219 Pax Labs, Class A, Acquisition Date: 4/18/19, Cost \$9,910 (1)(2		634,953	14,598
Monte Rosa Therapeutics (1)(4) 13,580 93 MoonLake Immunotherapeutics (1) 180,986 9,230 Morphic Holding (1) 114,700 6,576 MorphoSys, ADR (1) 1,554,800 11,614 Nkarta (1)(4) 1,645,141 3,603 Prothena (1) 105,013 7,170 Relay Therapeutics (1) 809,713 10,170 Repare Therapeutics (1)(4) 722,939 7,649 Replimune Group (1) 498,429 11,574 Syndax Pharmaceuticals (1) 644,500 13,489 Tenaya Therapeutics (1)(4) 883,580 5,187 Verve Therapeutics (1)(4) 514,029 9,638 Xencor (1) 1,198,858 29,935 Zentalis Pharmaceuticals (1)(4) 421,685 11,896 468,973 Health Care Equipment & Supplies 2.2% Atrion (4) 68,517 38,760 Avanos Medical (1) 940,800 24,047 Embecta 1,351,608 29,195 Lantheus Holdings (1) 598,419 50,219 Pax Labs, Class A, Acquisition Date: 4/18/19, Cost \$9,910 (1)(2) (5) 2,6			9,662
MoonLake Immunotherapeutics (1) 180,986 9,230 Morphic Holding (1) 114,700 6,576 MorphoSys, ADR (1) 1,554,800 11,614 Nkarta (1)(4) 1,645,141 3,603 Prothena (1) 105,013 7,170 Relay Therapeutics (1) 809,713 10,170 Repare Therapeutics (1)(4) 722,939 7,648 Replimune Group (1) 498,429 11,574 Syndax Pharmaceuticals (1) 644,500 13,488 Tenaya Therapeutics (1)(4) 883,580 5,187 Verve Therapeutics (1)(4) 514,029 9,638 Xencor (1) 1,198,858 29,935 Zentalis Pharmaceuticals (1)(4) 421,685 11,896 Health Care Equipment & Supplies 2.2% 68,517 38,760 Avanos Medical (1) 940,800 24,047 Embecta 1,351,608 29,195 Lantheus Holdings (1) 598,419 50,219 Pax Labs, Class A, Acquisition Date: 4/18/19, Cost \$9,910 (1)(2) (5) 2,631,808 1,263 QuidelOrtho (1) 699,768 57,983 Utah Medical Products (3)		13.580	93
Morphic Holding (1) 114,700 6,576 MorphoSys, ADR (1) 1,554,800 11,614 Nkarta (1)(4) 1,645,141 3,603 Prothena (1) 105,013 7,170 Relay Therapeutics (1) 809,713 10,170 Repare Therapeutics (1)(4) 722,939 7,649 Replimune Group (1) 498,429 11,574 Syndax Pharmaceuticals (1) 644,500 13,489 Tenaya Therapeutics (1)(4) 883,580 5,187 Verve Therapeutics (1)(4) 514,029 9,638 Xencor (1) 1,198,858 29,935 Zentalis Pharmaceuticals (1)(4) 421,685 11,896 Health Care Equipment & Supplies 2.2% 468,973 Atrion (4) 68,517 38,760 Avanos Medical (1) 940,800 24,047 Embecta 1,351,608 29,195 Lantheus Holdings (1) 598,419 50,219 Pax Labs, Class A, Acquisition Date: 4/18/19, Cost \$9,910 (1)(2) (5) 2,631,808 1,263 QuidelOrtho (1) 699,768 57,983 Utah Medical Products (3) 235,955 21,991		´	
MorphoSys, ADR (1) 1,554,800 11,614 Nkarta (1)(4) 1,645,141 3,603 Prothena (1) 105,013 7,170 Relay Therapeutics (1) 809,713 10,170 Repare Therapeutics (1)(4) 722,939 7,649 Replimune Group (1) 498,429 11,574 Syndax Pharmaceuticals (1) 644,500 13,489 Tenaya Therapeutics (1)(4) 883,580 5,187 Verve Therapeutics (1)(4) 514,029 9,638 Xencor (1) 1,198,858 29,935 Zentalis Pharmaceuticals (1)(4) 421,685 11,896 468,973 Health Care Equipment & Supplies 2.2% 68,517 38,760 Avanos Medical (1) 940,800 24,047 Embecta 1,351,608 29,195 Lantheus Holdings (1) 598,419 50,219 Pax Labs, Class A, Acquisition Date: 4/18/19, Cost \$9,910 (1)(2) 2,631,808 1,263 QuidelOrtho (1) 699,768 57,983 Utah Medical Products (3) 235,955 21,991			
Nkarta (1)(4) 1,645,141 3,603 Prothena (1) 105,013 7,170 Relay Therapeutics (1) 809,713 10,170 Repare Therapeutics (1)(4) 722,939 7,649 Replimune Group (1) 498,429 11,574 Syndax Pharmaceuticals (1) 644,500 13,489 Tenaya Therapeutics (1)(4) 883,580 5,187 Verve Therapeutics (1)(4) 514,029 9,638 Xencor (1) 1,198,858 29,935 Zentalis Pharmaceuticals (1)(4) 421,685 11,896 468,973 Health Care Equipment & Supplies 2.2% Atrion (4) 68,517 38,760 Avanos Medical (1) 940,800 24,047 Embecta 1,351,608 29,195 Lantheus Holdings (1) 598,419 50,219 Pax Labs, Class A, Acquisition Date: 4/18/19, Cost \$9,910 (1)(2) 2,631,808 1,263 QuidelOrtho (1) 699,768 57,983 Utah Medical Products (3) 235,955 21,991		´	. – – – – – – – – – –
Prothena (1) 105,013 7,170 Relay Therapeutics (1) 809,713 10,170 Repare Therapeutics (1)(4) 722,939 7,649 Replimune Group (1) 498,429 11,574 Syndax Pharmaceuticals (1) 644,500 13,489 Tenaya Therapeutics (1)(4) 883,580 5,187 Verve Therapeutics (1)(4) 514,029 9,638 Xencor (1) 1,198,858 29,935 Zentalis Pharmaceuticals (1)(4) 421,685 11,896 468,973 Health Care Equipment & Supplies 2.2% Atrion (4) 68,517 38,760 Avanos Medical (1) 940,800 24,047 Embecta 1,351,608 29,195 Lantheus Holdings (1) 598,419 50,219 Pax Labs, Class A, Acquisition Date: 4/18/19, Cost \$9,910 (1)(2) 2,631,808 1,263 QuidelOrtho (1) 699,768 57,983 Utah Medical Products (3) 235,955 21,991			. – – – – – – – – –
Relay Therapeutics (1) 809,713 10,170 Repare Therapeutics (1)(4) 722,939 7,649 Replimune Group (1) 498,429 11,574 Syndax Pharmaceuticals (1) 644,500 13,489 Tenaya Therapeutics (1)(4) 883,580 5,187 Verve Therapeutics (1)(4) 514,029 9,638 Xencor (1) 1,198,858 29,935 Zentalis Pharmaceuticals (1)(4) 421,685 11,896 468,973 Health Care Equipment & Supplies 2.2% Atrion (4) 68,517 38,760 Avanos Medical (1) 940,800 24,047 Embecta 1,351,608 29,195 Lantheus Holdings (1) 598,419 50,219 Pax Labs, Class A, Acquisition Date: 4/18/19, Cost \$9,910 (1)(2) 2,631,808 1,263 QuidelOrtho (1) 699,768 57,983 Utah Medical Products (3) 235,955 21,991			. – – – – – – – – – –
Repare Therapeutics (1)(4) 722,939 7,649 Replimune Group (1) 498,429 11,574 Syndax Pharmaceuticals (1) 644,500 13,489 Tenaya Therapeutics (1)(4) 883,580 5,187 Verve Therapeutics (1)(4) 514,029 9,638 Xencor (1) 1,198,858 29,935 Zentalis Pharmaceuticals (1)(4) 421,685 11,896 468,973 Health Care Equipment & Supplies 2.2% Atrion (4) 68,517 38,760 Avanos Medical (1) 940,800 24,047 Embecta 1,351,608 29,195 Lantheus Holdings (1) 598,419 50,219 Pax Labs, Class A, Acquisition Date: 4/18/19, Cost \$9,910 (1)(2) 2,631,808 1,263 QuidelOrtho (1) 699,768 57,983 Utah Medical Products (3) 235,955 21,991	·		
Replimune Group (1) 498,429 11,574 Syndax Pharmaceuticals (1) 644,500 13,489 Tenaya Therapeutics (1)(4) 883,580 5,187 Verve Therapeutics (1)(4) 514,029 9,638 Xencor (1) 1,198,858 29,935 Zentalis Pharmaceuticals (1)(4) 421,685 11,896 Health Care Equipment & Supplies 2.2% Atrion (4) 68,517 38,760 Avanos Medical (1) 940,800 24,047 Embecta 1,351,608 29,195 Lantheus Holdings (1) 598,419 50,219 Pax Labs, Class A, Acquisition Date: 4/18/19, Cost \$9,910 (1)(2) 2,631,808 1,263 QuidelOrtho (1) 699,768 57,983 Utah Medical Products (3) 235,955 21,991			. – – – – – – – – – –
Syndax Pharmaceuticals (1) 644,500 13,489 Tenaya Therapeutics (1)(4) 883,580 5,187 Verve Therapeutics (1)(4) 514,029 9,638 Xencor (1) 1,198,858 29,935 Zentalis Pharmaceuticals (1)(4) 421,685 11,896 Health Care Equipment & Supplies 2.2% Atrion (4) 68,517 38,760 Avanos Medical (1) 940,800 24,047 Embecta 1,351,608 29,195 Lantheus Holdings (1) 598,419 50,219 Pax Labs, Class A, Acquisition Date: 4/18/19, Cost \$9,910 (1)(2) 2,631,808 1,263 QuidelOrtho (1) 699,768 57,983 Utah Medical Products (3) 235,955 21,991		'	. – – – – – – ′ – – –
Tenaya Therapeutics (1)(4) 883,580 5,187 Verve Therapeutics (1)(4) 514,029 9,638 Xencor (1) 1,198,858 29,935 Zentalis Pharmaceuticals (1)(4) 421,685 11,896 Health Care Equipment & Supplies 2.2% Atrion (4) 68,517 38,760 Avanos Medical (1) 940,800 24,047 Embecta 1,351,608 29,195 Lantheus Holdings (1) 598,419 50,219 Pax Labs, Class A, Acquisition Date: 4/18/19, Cost \$9,910 (1)(2) 2,631,808 1,263 QuidelOrtho (1) 699,768 57,983 Utah Medical Products (3) 235,955 21,991			
Verve Therapeutics (1)(4) 514,029 9,638 Xencor (1) 1,198,858 29,935 Zentalis Pharmaceuticals (1)(4) 421,685 11,896 Health Care Equipment & Supplies 2.2% Atrion (4) 68,517 38,760 Avanos Medical (1) 940,800 24,047 Embecta 1,351,608 29,195 Lantheus Holdings (1) 598,419 50,219 Pax Labs, Class A, Acquisition Date: 4/18/19, Cost \$9,910 (1)(2) 2,631,808 1,263 QuidelOrtho (1) 699,768 57,983 Utah Medical Products (3) 235,955 21,991			. – – – – – – ′ – – –
Xencor (1) 1,198,858 29,935 Zentalis Pharmaceuticals (1)(4) 421,685 11,896 Health Care Equipment & Supplies 2.2% Atrion (4) 68,517 38,760 Avanos Medical (1) 940,800 24,047 Embecta 1,351,608 29,195 Lantheus Holdings (1) 598,419 50,219 Pax Labs, Class A, Acquisition Date: 4/18/19, Cost \$9,910 (1)(2) 2,631,808 1,263 QuidelOrtho (1) 699,768 57,983 Utah Medical Products (3) 235,955 21,991			
Zentalis Pharmaceuticals (1)(4) 421,685 11,896 Health Care Equipment & Supplies 2.2% Atrion (4) 68,517 38,760 Avanos Medical (1) 940,800 24,047 Embecta 1,351,608 29,195 Lantheus Holdings (1) 598,419 50,219 Pax Labs, Class A, Acquisition Date: 4/18/19, Cost \$9,910 (1)(2) 2,631,808 1,263 QuidelOrtho (1) 699,768 57,983 Utah Medical Products (3) 235,955 21,991	·		. – – – – – – – – – –
Health Care Equipment & Supplies 2.2% Atrion (4) 68,517 38,760 Avanos Medical (1) 940,800 24,047 Embecta 1,351,608 29,195 Lantheus Holdings (1) 598,419 50,219 Pax Labs, Class A, Acquisition Date: 4/18/19, Cost \$9,910 (1)(2) (5) 2,631,808 1,263 QuidelOrtho (1) 699,768 57,983 Utah Medical Products (3) 235,955 21,991			. – – – – – – – – –
Health Care Equipment & Supplies 2.2% Atrion (4) 68,517 38,760 Avanos Medical (1) 940,800 24,047 Embecta 1,351,608 29,195 Lantheus Holdings (1) 598,419 50,219 Pax Labs, Class A, Acquisition Date: 4/18/19, Cost \$9,910 (1)(2) 2,631,808 1,263 (5) 2,631,808 1,263 QuidelOrtho (1) 699,768 57,983 Utah Medical Products (3) 235,955 21,991			
Avanos Medical (1) 940,800 24,047 Embecta 1,351,608 29,195 Lantheus Holdings (1) 598,419 50,219 Pax Labs, Class A, Acquisition Date: 4/18/19, Cost \$9,910 (1)(2) 2,631,808 1,263 QuidelOrtho (1) 699,768 57,983 Utah Medical Products (3) 235,955 21,991	Health Care Equipment & Supplies 2.2%		400,570
Avanos Medical (1) 940,800 24,047 Embecta 1,351,608 29,195 Lantheus Holdings (1) 598,419 50,219 Pax Labs, Class A, Acquisition Date: 4/18/19, Cost \$9,910 (1)(2) 2,631,808 1,263 QuidelOrtho (1) 699,768 57,983 Utah Medical Products (3) 235,955 21,991		68.517	38.760
Embecta 1,351,608 29,195 Lantheus Holdings (1) 598,419 50,219 Pax Labs, Class A, Acquisition Date: 4/18/19, Cost \$9,910 (1)(2) 2,631,808 1,263 QuidelOrtho (1) 699,768 57,983 Utah Medical Products (3) 235,955 21,991			
Lantheus Holdings (1) 598,419 50,219 Pax Labs, Class A, Acquisition Date: 4/18/19, Cost \$9,910 (1)(2) 2,631,808 1,263 QuidelOrtho (1) 699,768 57,983 Utah Medical Products (3) 235,955 21,991			29,195
Pax Labs, Class A, Acquisition Date: 4/18/19, Cost \$9,910 (1)(2) (5) 2,631,808 1,263 QuidelOrtho (1) 699,768 57,983 Utah Medical Products (3) 235,955 21,991			. – – – – – – – – – –
(5) 2,631,808 1,263 QuidelOrtho (1) 699,768 57,983 Utah Medical Products (3) 235,955 21,991	9		
QuidelOrtho (1) 699,768 57,983 Utah Medical Products (3) 235,955 21,991		2,631,808	1,263
Utah Medical Products (3) 235,955 21,991			57,983
·			21,991
			223.458

	Shares/Par	\$ Value
(Cost and value in \$000s)		
Health Care Providers & Services 2.9%		
Agiliti (1)	1,470,971	24,271
Alignment Healthcare (1)	3,210,110	18,458
Capsule, Acquisition Date: 4/7/21, Cost \$3,065 (1)(2)(5)	211,518	620
Ensign Group	718,972	68,633
Innovage Holding (1)	3,432,942	25,747
Option Care Health (1)	615,843	20,009
Pennant Group (1)	1,507,762	18,516
Select Medical Holdings	3,851,734	122,716
		298,970
Health Care Technology 0.7%		
Certara (1)	507,880	9,248
Multiplan (1)(4)	17,151,000	36,189
Phreesia (1)	1,030,734	31,963
		77,400
Life Sciences Tools & Services 0.0%		
Seer (1)	904,256	3,861
		3,861
Pharmaceuticals 0.1%		
Structure Therapeutics, ADR (1)	110,892	4,610
Ventyx Biosciences (1)	275,400	9,033
		13,643
Total Health Care		1,086,305
INDUSTRIALS & BUSINESS SERVICES 14.0%		1,000,000
Aerospace & Defense 0.8%		
Parsons (1)	1,055,060	50,791
Triumph Group (1)	2.333.559	28,866
		79,657
Building Products 2.3%		19,031
CSW Industrials	354,648	58,939
Insteel Industries	338,658	10,539
JELD-WEN Holding (1)	834,717	14,641
UFP Industries	1,189,202	115,412
Zurn Elkay Water Solutions	1,326,735	35,676
·		235,207
Commercial Services & Supplies 1.7%		200,201
Aris Water Solution, Class A	2,293,278	23,667
Brady, Class A	1,219,492	58,011
MSA Safety	238,503	41,490
Tetra Tech	162,941	26,680
UniFirst	142.700	22,120
	142,700	

	Shares/Par	\$ Value
(Cost and value in \$000s)		
Construction & Engineering 0.5%		
Valmont Industries	168,616	49,076
		49,076
Electrical Equipment 0.3%		
Thermon Group Holdings (1)	1,300,307	34,588
		34,588
Ground Transportation 0.9%		
Convoy, Warrants, 03/15/33, Acquisition Date: 3/24/23,		
Cost \$— (1)(2)(5)	86,098	
Landstar System	487,300	93,825
Machinery 3.5%		93,825
Alamo Group	251,600	46,272
Blue Bird (1)	841,761	18,923
Esab	765,471	50,934
ESCO Technologies	556,587	57,679
Helios Technologies	920,197	60,816
Hydrofarm Holdings Group (1)	537,657	420
John Bean Technologies	87,300	10,589
RBC Bearings (1)	227,551	49,486
Shyft Group	842,000	18,575
SPX Technologies (1)	541,300	45,994
Marine Transportation 0.2%		359,688
Matson	239,107	18,586
MidiSUI	239,107	
Passenger Airlines 0.8%		18,586
Allegiant Travel (1)	433,007	54,680
Sun Country Airlines Holdings (1)(4)	1,128,411	25,367
		80,047
Professional Services 0.8%		
Checkr, Acquisition Date: 6/29/18, Cost \$866 (1)(2)(5)	211,422	1,142
Conduent (1)	6,845,238	23,274
FTI Consulting (1)	200,877	38,207
Paycor HCM (1)(4)	879,665	20,821
Trading Companies 9 Distributors 0.00/		83,444
Trading Companies & Distributors 2.2%	004 == 4	2.22:
Air Lease	231,574	9,691
Beacon Roofing Supply (1)	1,322,745	109,762
Herc Holdings	216,910	29,684
McGrath RentCorp	502,301	46,453

	Shares/Par	\$ Value
(Cost and value in \$000s)		
Rush Enterprises, Class A	465,742	28,289
		223,879
Total Industrials & Business Services		1,429,965
INFORMATION TECHNOLOGY 5.3%		1,120,000
Communications Equipment 0.3%		
Viavi Solutions (1)	2,776,400	31,457
vian conditions (1)		31,457
Electronic Equipment, Instruments & Components 3.0%		31,437
Belden	624,666	59,749
Knowles (1)	1,454,800	26,274
Littelfuse	387,234	112,805
Mirion Technologies (1)	4,567,510	38,595
Vontier	2,131,000	68,640
		306,063
IT Services 0.0%		
Themis Solutions, Acquisition Date: 4/14/21, Cost \$3,039 (1)(2)(5)	135,360	2,412
πιστιιο σοιαιότιο, ποφαιδιαστι Εατά η 1-η Ε 1, σσοί φο,σσο (1)(Ε)(σ)		2,412
Semiconductors & Semiconductor Equipment 1.0%		2,412
Entegris	68,118	7,549
Lattice Semiconductor (1)	314,557	30,219
MACOM Technology Solutions Holdings (1)	260,600	17,077
MaxLinear (1)	432,737	13,657
Onto Innovation (1)	344,901	40,171
		108,673
Software 1.0%		
Apiture, Acquisition Date: 7/1/20 - 6/30/22, Cost \$8,333 (1)(2)(5)	523,101	9,290
DoubleVerify Holdings (1)	857,395	33,370
Envestnet (1)	199,700	11,852
Gusto, Acquisition Date: 8/18/20 - 11/9/20, Cost \$7,474 (1)(2)(5)	559,515	10,536
nCino (1)	658,774	19,842
Socure, Acquisition Date: 12/22/21, Cost \$2,410 (1)(2)(5)	149,990	1,122
Workiva (1)	162,436	16,513
		102,525
Total Information Technology MATERIALS 4.2%		551,130
Chemicals 1.7%		
Element Solutions	3,174,200	60,945
Hawkins	514,586	24,540
Orion	1,806,391	38,332
Quaker Chemical	271,600	52,935
		176,752
		1,0,,02

	Shares/Par	\$ Value
(Cost and value in \$000s)		
Containers & Packaging 0.3%		
Myers Industries	1,734,589	33,703
,		33,703
Metals & Mining 1.8%		
Carpenter Technology	565,565	31,745
Constellium (1)	4,815,085	82,820
Reliance Steel & Aluminum	282,865	76,823
		191,388
Paper & Forest Products 0.4%		
Clearwater Paper (1)(3)	1,274,979	39,932
West Fraser Timber (CAD)	13,010	1,118
West Fraser Timber	44,734	3,846
		44,896
Total Materials		446,739
REAL ESTATE 10.0%		
Diversified Real Estate Investment Trusts 0.6%		
Essential Properties Realty Trust, REIT	2,479,123	58,359
		58,359
Hotel & Resort Real Estate Investment Trusts 1.1%		
Apple Hospitality, REIT	3,795,206	57,346
Pebblebrook Hotel Trust, REIT (4)	3,887,300	54,189
		111,535
Industrial Real Estate Investment Trusts 1.9%		
EastGroup Properties, REIT	478,200	83,015
Terreno Realty, REIT	1,958,300	117,694
		200,709
Office Real Estate Investment Trusts 0.4%		
IQHQ, REIT, Acquisition Date: 10/30/19 - 8/21/20,		
Cost \$13,130 (1)(2)(5)	866,287	16,347
JBG SMITH Properties, REIT (4)	1,399,942	21,055
		37,402
Real Estate Management & Development 2.6%		
DigitalBridge Group (4)	1,406,138	20,684
FirstService (4)	478,200	73,686
Opendoor Technologies, Class A (1)(4)	6,283,097	25,258
St. Joe	1,828,068	88,369
Tricon Residential (4)	6,486,197	57,143
Position Mal Posit February 17 1 2 20%		265,140
Residential Real Estate Investment Trusts 0.6%		
Apartment Investment & Management, Class A, REIT	924,765	7,879
Elme Communities, REIT	190,600	3,133

	Shares/Par	\$ Value
(Cost and value in \$000s)		
NexPoint Residential Trust, REIT	601,800	27,370
UMH Properties, REIT	1,350,800	21,586
		59,968
Residential Reits 0.3%		
Independence Realty Trust, REIT	1,875,700	34,175
		34,175
Retail Real Estate Investment Trusts 0.5%		
Saul Centers, REIT (3)	1,326,706	48,863
		48,863
Retail Reits 0.4%		
NETSTREIT, REIT	2,158,336	38,569
		38,569
Specialized Real Estate Investment Trusts 1.6%		
CubeSmart, REIT	1,598,200	71,375
PotlatchDeltic, REIT	1,126,146	59,517
Safehold, REIT (4)	1,583,650	37,580
		168,472
Total Real Estate		1,023,192
UTILITIES 4.9%		
Electric Utilities 2.5%		
IDACORP	1,148,100	117,795
MGE Energy	1,244,337	98,440
PNM Resources	922,175	41,590
		257,825
Gas Utilities 1.1%		
Chesapeake Utilities	310,763	36,981
ONE Gas	911,282	69,996
RGC Resources	269,456	5,397
Multi-Utilities 0.6%		112,374
NorthWestern	1,176,684	66,789
Noturvesterii	1,170,004	
Water Utilities 0.7%		66,789
	422 162	20.454
Artesian Resources, Class A California Water Service Group	433,163 742,139	20,454
Middlesex Water	170,963	13,790
		72,560
Total Utilities		509,548
Total Common Stocks (Cost \$7,149,494)		9,813,420
Total Collins of Otota (Cost W1, 170,707)		

	Shares/Par	\$ Value
(Cost and value in \$000s)		
CONVERTIBLE BONDS 0.0%		
Convoy, 15.00%, 9/30/26, Acquisition Date: 3/24/23, Cost \$597 (1)(2)(5)	597,290	597
Total Convertible Bonds (Cost \$597)		597
CONVERTIBLE PREFERRED STOCKS 3.2%		
CONSUMER DISCRETIONARY 0.2%		
Hotels, Restaurants & Leisure 0.0%		
Torchys Holdings, Acquisition Date: 11/13/20, Cost \$2,539 (1)(2) (5)(7)	282,711	1,532
Leiouve Bradusto 0 19/		1,532
Leisure Products 0.1% Rad Power Bikes, Series C, Acquisition Date: 1/22/21,		
Cost \$5,494 (1)(2)(5) Rad Power Bikes, Series D, Acquisition Date: 9/16/21,	1,138,910	2,631
Cost \$10,332 (1)(2)(5)	1,078,119	4,549
		7,180
Specialty Retail 0.1%		
1661, Series F, Acquisition Date: 5/28/21, Cost \$12,383 (1)(2)(5) Minted, Series E, Acquisition Date: 10/30/18, Cost \$5,471 (1)(2)(5)	2,127,647 406,249	3,915
Millied, Series E, Acquisition Date. 10/30/10, Cost \$3,471 (1)(2)(3)	400,249	7,380
Total Consumer Discretionary		16,092
CONSUMER STAPLES 0.5%		10,002
Food Products 0.5%		
Farmers Business Network, Series D, Acquisition Date: 11/3/17,		
Cost \$15,529 (1)(2)(5)	841,026	42,076
Farmers Business Network, Series E, Acquisition Date: 2/11/19, Cost \$3,362 (1)(2)(5)	144,247	7,217
Farmers Business Network, Series F, Acquisition Date: 7/31/20,		
Cost \$881 (1)(2)(5)	26,661	1,334
Total Consumer Staples FINANCIALS 0.4%		50,627
Banks 0.1%		
CRB Group, Acquisition Date: 1/28/22, Cost \$11,470 (1)(2)(5)	109,095	8,440
		8,440
Financial Services 0.1%		
Stash Financial, Series F, Acquisition Date: 4/24/20,	445 004	6 407
Cost \$11,157 (1)(2)(5) Stash Financial, Series G, Acquisition Date: 1/26/21,	445,224	6,487
Cost \$12,559 (1)(2)(5)	335,107	4,882
		11,369

	Shares/Par	\$ Value
(Cost and value in \$000s)		
Insurance 0.2%		
Coalition, Series E, Acquisition Date: 9/7/21, Cost \$21,422 (1)(2)		
(5)	1,296,510	21,885
		21,885
Total Financials		41,694
HEALTH CARE 0.7%		
Biotechnology 0.0%		
Laronde, Series B, Acquisition Date: 7/28/21, Cost \$9,269 (1)(2)(5)	331,043	1,854
		1,854
Health Care Providers & Services 0.1%		
Capsule, Series 1-D, Acquisition Date: 4/7/21, Cost \$3,065 (1)(2)	011 510	600
(5) Honor Technology, Series D, Acquisition Date: 10/16/20,	211,518	620
Cost \$8,981 (1)(2)(5)	3,729,550	4,065
Honor Technology, Series E, Acquisition Date: 9/29/21,		
Cost \$10,347 (1)(2)(5)	3,272,913	3,568
		8,253
Life Sciences Tools & Services 0.6%		
Cleerly, Series C, Acquisition Date: 7/8/22, Cost \$11,917 (1)(2)(5)	1,011,567	11,917
National Resilience, Series B, Acquisition Date: 10/23/20, Cost \$6,453 (1)(2)(5)	472,388	28,688
National Resilience, Series C, Acquisition Date: 6/9/21,		
Cost \$13,636 (1)(2)(5)	307,043	18,647
		59,252
Total Health Care		69,359
INDUSTRIALS & BUSINESS SERVICES 0.6%		
Aerospace & Defense 0.2%		
ABL Space Systems, Series B, Acquisition Date: 3/24/21,		
Cost \$14,587 (1)(2)(5)	323,903	10,401
Epirus, Series C-2, Acquisition Date: 1/28/22, Cost \$14,645 (1)(2) (5)	2,622,728	13,192
.(9)		23,593
Electrical Equipment 0.3%		
CELLINK, Series D, Acquisition Date: 1/20/22, Cost \$12,776 (1)		
(2)(5)	613,518	8,166
Tonian Holdings, Series A, Non-Voting Shares, Acquisition Date:		
1/15/21 - 7/20/21, Cost \$8,392 (1)(2)(3)(5) Tonian Holdings, Series A, Voting Shares, Acquisition Date:	8,531,194	10,238
1/15/21 - 1/26/22, Cost \$15,325 (1)(2)(3)(5)	15,050,275	18,060
		36,464

Cost and value in \$000s Ground Transportation 0.1% Convoy, Series D, Acquisition Date: 10/30/19, Cost \$19,800 (1)(2) (5)		Shares/Par	\$ Value
(5) 1,462,353 7,575 Professional Services 0.0% Checkr, Series C, Acquisition Date: 4/10/18, Cost \$4,046 (1)(2)(5) 889,080 4,801 Total Industrials & Business Services 72,433 INFORMATION TECHNOLOGY 0.6% IT Services 0.1% Themis Solutions, Series AA, Acquisition Date: 4/14/21, Cost \$864 (1)(2)(5) 30,470 543 Themis Solutions, Series BB, Acquisition Date: 4/14/21, Cost \$868 (1)(2)(5) 3,3030 54 Themis Solutions, Series BB, Acquisition Date: 4/14/21, Cost \$868 (1)(2)(5) 3,310 59 Themis Solutions, Series BB, Acquisition Date: 4/14/21, Cost \$868 (1)(2)(5) 3,310 59 Themis Solutions, Series BB, Acquisition Date: 4/14/21, Cost \$8,658 (1)(2)(5) 3,310 59 Themis Solutions, Series BB, Acquisition Date: 4/14/21, Cost \$8,658 (1)(2)(5) 3,310 59 Themis Solutions, Series BB, Acquisition Date: 4/14/21, Cost \$8,658 (1)(2)(5) 3,310 59 Themis Solutions, Series BB, Acquisition Date: 4/14/21, Cost \$8,658 (1)(2)(5) 3,310 59 Themis Solutions, Series BB, Acquisition Date: 4/14/21, Cost \$8,658 (1)(2)(5) 3,385,620 6,872 Software 0.5% Gusto, Series BB, Acquisition Date: 8/18/20, Cost \$1,746 (1)(2)(5) 129,187 2,433 Gusto, Series BB, Acquisition Date: 8/18/20, Cost \$3,259 (1)(2)(5) 241,168 4,540 Gusto, Series C, Acquisition Date: 7/16/18, Cost \$4,12 (2)(5) 711,894 13,405 Gusto, Series D, Acquisition Date: 7/16/19, Cost \$7,227 (1)(2)(5) 542,859 10,222 Mesosphere, Series D, Acquisition Date: 10/30/20 - 3/2/21, Cost \$11,195 (1)(2)(5) 857,551 5,317 Nuro, Series D, Acquisition Date: 10/29/21, Cost \$6,458 (1)(2)(5) 309,802 1,921 SecurityScorecard, Series E, Acquisition Date: 3/5/21, Cost \$9,505 (1)(2)(5) 1,881,753 9,597 Socure, Series A, Acquisition Date: 12/22/21, Cost \$2,404 (1) (2)(6) 149,613 1,119 Socure, Series B, Acquisition Date: 12/22/21, Cost \$5,572 (1)(2)(5) 346,775 2,594 Socure, Series B, Acquisition Date: 12/22/21, Cost \$5,572 (1)(2)(5) 346,775 2,594	(Cost and value in \$000s)		
Total Industrials & Business Services 1,862,353 1,575 1,862,353 1,862 1,801 1,80	Ground Transportation 0.1%		
Professional Services 0.0% Checkr, Series C, Acquisition Date: 4/10/18, Cost \$4,046 (1)(2)(5) 889,080 4,801 Total Industrials & Business Services 72,433 INFORMATION TECHNOLOGY 0.6% IT Services 0.1% Themis Solutions, Series AA, Acquisition Date: 4/14/21, Cost \$684 (1)(2)(5) 30,470 543 Themis Solutions, Series AB, Acquisition Date: 4/14/21, Cost \$68 (1)(2)(5) 3,030 54 Themis Solutions, Series B, Acquisition Date: 4/14/21, Cost \$68 (1)(2)(5) 3,310 59 Themis Solutions, Series E, Acquisition Date: 4/14/21, Cost \$74 (1)(2)(5) 3,310 59 Themis Solutions, Series E, Acquisition Date: 4/14/21, Cost \$8,658 (1)(2)(5) 385,620 6,872 Software 0.5% Gusto, Series B, Acquisition Date: 8/18/20, Cost \$1,746 (1)(2)(5) 129,187 2,433 Gusto, Series B, Acquisition Date: 8/18/20, Cost \$3,259 (1)(2)(5) 241,168 4,541 Gusto, Series C, Acquisition Date: 7/16/18, Cost \$5,412 (2)(5) 711,894 13,405 Gusto, Series D, Acquisition Date: 7/16/18, Cost \$7,227 (1)(2)(5) 542,859 10,222 Mesosphere, Series D, Acquisition Date: 5/4/18, Cost \$13,430 (1) (2)(5) 1,214,930 753 Nuro, Series C, Acquisition Date: 10/30/20 3/2/21, Cost \$1,195 (1)(2)(5) 857,551 5,317 Nuro, Series D, Acquisition Date: 10/30/20 3/2/21, Cost \$9,505 (1)(2)(5) 1881,753 9,597 Socure, Series A, Acquisition Date: 12/22/21, Cost \$2,999 (1)(2) (5) 182,290 1,363 Socure, Series B, Acquisition Date: 12/22/21, Cost \$2,404 (1) (2)(5) 149,613 1,119 Socure, Series B, Acquisition Date: 12/22/21, Cost \$43 (1)(2)(5) 2,706 20 Socure, Series B, Acquisition Date: 12/22/21, Cost \$4,572 (1)(2)(5) 346,775 2,594	Convoy, Series D, Acquisition Date: 10/30/19, Cost \$19,800 (1)(2)		
Professional Services 0.0% Checkr, Series C, Acquisition Date: 4/10/18, Cost \$4,046 (1)(2)(5) 889,080 4,801	(5)	1,462,353	7,575
Checkr, Series C, Acquisition Date: 4/10/18, Cost \$4,046 (1)(2)(5) 889,080 4,801			7,575
Total Industrials & Business Services 72,433 INFORMATION TECHNOLOGY 0.6% IT Services 0.1% Themis Solutions, Series AA, Acquisition Date: 4/14/21, Cost \$684 (1)(2)(5) 30,470 543 Themis Solutions, Series BB, Acquisition Date: 4/14/21, Cost \$68 (1)(2)(5) 3,030 54 Themis Solutions, Series B, Acquisition Date: 4/14/21, Cost \$68 (1)(2)(5) 3,3310 59 Themis Solutions, Series B, Acquisition Date: 4/14/21, Cost \$74 (1)(2)(5) 3,3310 59 Themis Solutions, Series E, Acquisition Date: 4/14/21, Cost \$8,658 (1)(2)(5) 385,620 6,872 Software 0.5% Gusto, Series B, Acquisition Date: 8/18/20, Cost \$1,746 (1)(2)(5) 129,187 2,433 Gusto, Series B-2, Acquisition Date: 8/18/20, Cost \$3,259 (1)(2)(5) 241,168 4,541 Gusto, Series D, Acquisition Date: 7/16/18, Cost \$5,412 (2)(5) 711,894 13,405 Gusto, Series D, Acquisition Date: 7/16/19, Cost \$7,227 (1)(2)(5) 542,859 10,222 Mesosphere, Series D, Acquisition Date: 5/4/18, Cost \$13,430 (1) (2)(5) 1,214,930 753 Nurro, Series C, Acquisition Date: 10/30/20 - 3/2/21, Cost \$11,195 (1)(2)(5) 857,551 5,317 Nuro, Series D, Acquisition Date: 10/29/21, Cost \$6,458 (1)(2)(5) 309,802 1,921 SecurityScorecard, Series E, Acquisition Date: 3/5/21, Cost \$9,505 (1)(2)(5) 1,881,753 9,597 Socure, Series A, Acquisition Date: 12/22/21, Cost \$2,404 (1) (2)(5) 149,613 1,119 Socure, Series B, Acquisition Date: 12/22/21, Cost \$43 (1)(2)(5) 2,706 20 Socure, Series E, Acquisition Date: 10/27/21, Cost \$5,572 (1)(2)(5) 346,775 2,594			
Total Industrials & Business Services 72,433 INFORMATION TECHNOLOGY 0.6% IT Services 0.1% Themis Solutions, Series AA, Acquisition Date: 4/14/21, 30,470 543 Themis Solutions, Series AB, Acquisition Date: 4/14/21, 3,030 54 Themis Solutions, Series AB, Acquisition Date: 4/14/21, 3,030 54 Themis Solutions, Series B, Acquisition Date: 4/14/21, 3,310 59 Themis Solutions, Series E, Acquisition Date: 4/14/21, 3,35 3,310 59 Themis Solutions, Series E, Acquisition Date: 4/14/21, 3,35,620 6,872 Software 0.5% 3,35,620 6,872 5,288 58,658 (1)(2)(5) 3,35,620 6,872 5,288 5,288 5,289 5,2	Checkr, Series C, Acquisition Date: 4/10/18, Cost \$4,046 (1)(2)(5)	889,080	4,801
INFORMATION TECHNOLOGY 0.6% IT Services 0.1% Themis Solutions, Series AA, Acquisition Date: 4/14/21, Cost \$684 (1)(2)(5) 30,470 543 Themis Solutions, Series AB, Acquisition Date: 4/14/21, Cost \$684 (1)(2)(5) 3,030 54 Themis Solutions, Series B, Acquisition Date: 4/14/21, Cost \$74 (1)(2)(5) 3,310 59 Themis Solutions, Series E, Acquisition Date: 4/14/21, Cost \$8,658 (1)(2)(5) 3,310 59 Themis Solutions, Series E, Acquisition Date: 4/14/21, Cost \$8,658 (1)(2)(5) 385,620 6,872 Software 0.5% Gusto, Series B, Acquisition Date: 8/18/20, Cost \$1,746 (1)(2)(5) 129,187 2,433 Gusto, Series B-2, Acquisition Date: 8/18/20, Cost \$3,259 (1)(2)(5) 241,168 4,541 Gusto, Series C, Acquisition Date: 7/16/18, Cost \$5,412 (2)(5) 711,894 13,405 Gusto, Series D, Acquisition Date: 7/16/19, Cost \$7,227 (1)(2)(5) 542,859 10,222 Mesosphere, D, Acquisition Date: 5/4/18, Cost \$13,430 (1) (2)(5) 1,214,930 753 Nuro, Series C, Acquisition Date: 10/30/20 - 3/2/21, Cost \$11,195 (1)(2)(5) 857,551 5,317 Nuro, Series D, Acquisition Date: 10/29/21, Cost \$6,458 (1)(2)(5) 309,802 1,921 SecurityScorecard, Series E, Acquisition Date: 3/5/21, Cost \$9,505 (1)(2)(5) 1,881,753 9,597 Socure, Series A, Acquisition Date: 12/22/21, Cost \$2,929 (1)(2) (5) 182,290 1,363 Socure, Series B, Acquisition Date: 12/22/21, Cost \$2,404 (1) (2)(5) 2,706 20 Socure, Series B, Acquisition Date: 10/27/21, Cost \$43 (1)(2)(5) 346,775 2,594			4,801
Themis Solutions, Series AA, Acquisition Date: 4/14/21, Cost \$684 (1)(2)(5) Themis Solutions, Series AB, Acquisition Date: 4/14/21, Cost \$68 (1)(2)(5) Themis Solutions, Series B, Acquisition Date: 4/14/21, Cost \$68 (1)(2)(5) Themis Solutions, Series B, Acquisition Date: 4/14/21, Cost \$74 (1)(2)(5) Themis Solutions, Series E, Acquisition Date: 4/14/21, Cost \$8,658 (1)(2)(5) Software 0.5% Gusto, Series B, Acquisition Date: 8/18/20, Cost \$1,746 (1)(2)(5) Gusto, Series B-2, Acquisition Date: 8/18/20, Cost \$3,259 (1)(2)(5) Gusto, Series B-2, Acquisition Date: 7/16/18, Cost \$5,412 (2)(5) Gusto, Series D, Acquisition Date: 7/16/19, Cost \$7,227 (1)(2)(5) Mesosphere, Series D, Acquisition Date: 5/4/18, Cost \$13,430 (1) (2)(5) Nuro, Series C, Acquisition Date: 10/30/20-3/2/21, Cost \$11,195 (1)(2)(5) Nuro, Series D, Acquisition Date: 10/30/20-3/2/21, Cost \$9,505 (1)(2)(5) SecurityScorecard, Series E, Acquisition Date: 3/5/21, Cost \$9,505 (1)(2)(5) Socure, Series A, Acquisition Date: 12/22/21, Cost \$2,929 (1)(2) (5) Socure, Series B, Acquisition Date: 12/22/21, Cost \$2,929 (1)(2) (5) Socure, Series B, Acquisition Date: 12/22/21, Cost \$2,929 (1)(2) (5) Socure, Series B, Acquisition Date: 12/22/21, Cost \$2,929 (1)(2) (5) Socure, Series B, Acquisition Date: 12/22/21, Cost \$2,404 (1) (2)(5) Socure, Series B, Acquisition Date: 12/22/21, Cost \$2,404 (1) (2)(5) Socure, Series E, Acquisition Date: 12/22/21, Cost \$5,572 (1)(2)(5) Socure, Series E, Acquisition Date: 12/22/21, Cost \$5,572 (1)(2)(5) Socure, Series E, Acquisition Date: 10/27/21, Cost \$5,572 (1)(2)(5) Socure, Series E, Acquisition Date: 10/27/21, Cost \$5,572 (1)(2)(5) Socure, Series E, Acquisition Date: 10/27/21, Cost \$5,572 (1)(2)(5) Socure, Series E, Acquisition Date: 10/27/21, Cost \$5,572 (1)(2)(5) Socure, Series E, Acquisition Date: 10/27/21, Cost \$5,572 (1)(2)(5) Socure, Series E, Acquisition Date: 10/27/21, Cost \$5,572 (1)(2)(5) Socure, Series E, Acquisition Date: 10/27/21, Cost \$5,572 (1)(2)(5) Socure, Series E, Acquisition Date: 10/2			72,433
Themis Solutions, Series AA, Acquisition Date: 4/14/21, Cost \$684 (1)(2)(5) Themis Solutions, Series AB, Acquisition Date: 4/14/21, Cost \$68 (1)(2)(5) Themis Solutions, Series B, Acquisition Date: 4/14/21, Cost \$74 (1)(2)(5) Themis Solutions, Series B, Acquisition Date: 4/14/21, Cost \$8,658 (1)(2)(5) Software 0.5% Gusto, Series B, Acquisition Date: 8/18/20, Cost \$1,746 (1)(2)(5) Gusto, Series B-2, Acquisition Date: 8/18/20, Cost \$3,259 (1)(2)(5) Gusto, Series B-2, Acquisition Date: 7/16/18, Cost \$5,412 (2)(5) Gusto, Series D, Acquisition Date: 7/16/19, Cost \$7,227 (1)(2)(5) Mesosphere, Series D, Acquisition Date: 5/4/18, Cost \$13,430 (1) (2)(5) Nuro, Series C, Acquisition Date: 10/30/20-3/2/21, Cost \$11,195 (1)(2)(5) Nuro, Series D, Acquisition Date: 10/30/20-3/2/21, Cost \$9,505 (1)(2)(5) SecurityScorecard, Series E, Acquisition Date: 3/5/21, Cost \$9,505 (1)(2)(5) Socure, Series A, Acquisition Date: 12/22/21, Cost \$2,929 (1)(2) (5) Socure, Series B, Acquisition Date: 12/22/21, Cost \$2,929 (1)(2) (5) Socure, Series B, Acquisition Date: 12/22/21, Cost \$2,404 (1) (2)(5) Socure, Series B, Acquisition Date: 12/22/21, Cost \$2,404 (1) (2)(5) Socure, Series B, Acquisition Date: 12/22/21, Cost \$2,404 (1) (2)(5) Socure, Series B, Acquisition Date: 12/22/21, Cost \$2,404 (1) (2)(5) Socure, Series B, Acquisition Date: 12/22/21, Cost \$2,404 (1) (2)(5) Socure, Series B, Acquisition Date: 12/22/21, Cost \$2,404 (1) (2)(5) Socure, Series B, Acquisition Date: 12/22/21, Cost \$2,404 (1) (2)(5) Socure, Series B, Acquisition Date: 12/22/21, Cost \$5,572 (1)(2)(5) Socure, Series E, Acquisition Date: 12/22/21, Cost \$5,572 (1)(2)(5) Socure, Series E, Acquisition Date: 12/22/21, Cost \$5,572 (1)(2)(5) Socure, Series E, Acquisition Date: 10/27/21, Cost \$5,572 (1)(2)(5) Socure, Series E, Acquisition Date: 10/27/21, Cost \$5,572 (1)(2)(5) Socure, Series E, Acquisition Date: 10/27/21, Cost \$5,572 (1)(2)(5) Socure, Series E, Acquisition Date: 10/27/21, Cost \$5,572 (1)(2)(5) Socure, Series E, Acquisition Date: 10/27/2	INFORMATION TECHNOLOGY 0.6%		
Cost \$684 (1)(2)(5) 30,470 543 Themis Solutions, Series AB, Acquisition Date: 4/14/21, Cost \$68 (1)(2)(5) 3,030 54 Themis Solutions, Series B, Acquisition Date: 4/14/21, Cost \$74 (1)(2)(5) 3,310 59 Themis Solutions, Series E, Acquisition Date: 4/14/21, Cost \$8,658 (1)(2)(5) 385,620 6,872 Software 0.5% Gusto, Series B, Acquisition Date: 8/18/20, Cost \$1,746 (1)(2)(5) 129,187 2,433 Gusto, Series B-2, Acquisition Date: 8/18/20, Cost \$3,259 (1)(2)(5) 241,168 4,541 Gusto, Series C, Acquisition Date: 7/16/18, Cost \$5,412 (2)(5) 711,894 13,405 Gusto, Series D, Acquisition Date: 7/16/19, Cost \$7,227 (1)(2)(5) 542,859 10,222 Mesosphere, Series D, Acquisition Date: 5/4/18, Cost \$13,430 (1) (2)(5) 1,214,930 753 Nuro, Series C, Acquisition Date: 10/30/20 - 3/2/21, Cost \$11,195 (1)(2)(5) 857,551 5,317 Nuro, Series D, Acquisition Date: 10/29/21, Cost \$6,458 (1)(2)(5) 309,802 1,921 SecurityScorecard, Series E, Acquisition Date: 3/5/21, Cost \$9,505 (1)(2)(5) 1,881,753 9,597 Socure, Series A, Acquisition Date: 12/22/21, Cost \$2,929 (1)(2) (5) 182,290 1,363 Socure, Series B, Acquisition Date: 12/22/21, Cost \$2,404 (1) (2)(5) 2,706 20 Socure, Series E, Acquisition Date: 12/22/21, Cost \$436 (1)(2)(5) 346,775 2,594 Socure, Series E, Acquisition Date: 12/22/21, Cost \$5,572 (1)(2)(5) 346,775 2,594	IT Services 0.1%		
Themis Solutions, Series AB, Acquisition Date: 4/14/21, Cost \$68 (1)(2)(5) 3,030 54 Themis Solutions, Series B, Acquisition Date: 4/14/21, Cost \$74 (1)(2)(5) 3,310 59 Themis Solutions, Series E, Acquisition Date: 4/14/21, Cost \$8,658 (1)(2)(5) 385,620 6,872 T,528 Software 0.5% Gusto, Series B, Acquisition Date: 8/18/20, Cost \$1,746 (1)(2)(5) 129,187 2,433 Gusto, Series B, Acquisition Date: 8/18/20, Cost \$3,259 (1)(2)(5) 241,168 4,541 Gusto, Series C, Acquisition Date: 7/16/18, Cost \$5,412 (2)(5) 711,894 13,405 Gusto, Series D, Acquisition Date: 7/16/19, Cost \$7,227 (1)(2)(5) 542,859 10,222 Mesosphere, Series D, Acquisition Date: 5/4/18, Cost \$13,430 (1) (2)(5) 1,214,930 753 Nuro, Series C, Acquisition Date: 10/30/20 - 3/2/21, Cost \$11,195 (1)(2)(5) 857,551 5,317 Nuro, Series D, Acquisition Date: 10/29/21, Cost \$6,458 (1)(2)(5) 309,802 1,921 SecurityScorecard, Series E, Acquisition Date: 3/5/21, Cost \$9,505 (1)(2)(5) 1,881,753 9,597 Socure, Series A, Acquisition Date: 12/22/21, Cost \$2,929 (1)(2) (5) 182,290 1,363 Socure, Series B, Acquisition Date: 12/22/21, Cost \$2,404 (1) (2)(5) 2,706 20 Socure, Series E, Acquisition Date: 12/22/21, Cost \$43 (1)(2)(5) 346,775 2,594 Socure, Series E, Acquisition Date: 10/27/21, Cost \$5,572 (1)(2)(5) 346,775 2,594			
Cost \$68 (1)(2)(5) 3,030 54 Themis Solutions, Series B, Acquisition Date: 4/14/21, Cost \$74 (1)(2)(5) 3,310 59 Themis Solutions, Series E, Acquisition Date: 4/14/21, Cost \$8,658 (1)(2)(5) 385,620 6,872 Software 0.5% Gusto, Series B, Acquisition Date: 8/18/20, Cost \$1,746 (1)(2)(5) 129,187 2,433 Gusto, Series B, Acquisition Date: 8/18/20, Cost \$3,259 (1)(2)(5) 241,168 4,541 Gusto, Series B-2, Acquisition Date: 7/16/18, Cost \$5,412 (2)(5) 711,894 13,405 Gusto, Series D, Acquisition Date: 7/16/19, Cost \$7,227 (1)(2)(5) 542,859 10,222 Mesosphere, Series D, Acquisition Date: 5/4/18, Cost \$13,430 (1) (2)(5) 1,214,930 753 Nuro, Series C, Acquisition Date: 10/30/20 - 3/2/21, Cost \$11,195 (1)(2)(5) 857,551 5,317 Nuro, Series D, Acquisition Date: 10/29/21, Cost \$6,458 (1)(2)(5) 309,802 1,921 SecurityScorrecard, Series E, Acquisition Date: 3/5/21, Cost \$9,505 (1)(2)(5) 1,881,753 9,597 Socure, Series A, Acquisition Date: 12/22/21, Cost \$2,929 (1)(2) (5) 182,290 1,363 Socure, Series B, Acquisition Date: 12/22/21, Cost \$2,404 (1) (2)(5) 2,706 20 Socure, Series E, Acquisition Date: 12/22/21, Cost \$43 (1)(2)(5) 2,706 20 Socure, Series E, Acquisition Date: 10/27/21, Cost \$5,572 (1)(2)(5) 346,775 2,594		30,470	543
Themis Solutions, Series B, Acquisition Date: 4/14/21, Cost \$74 (1)(2)(5) Themis Solutions, Series E, Acquisition Date: 4/14/21, Cost \$8,658 (1)(2)(5) Software 0.5% Gusto, Series B, Acquisition Date: 8/18/20, Cost \$1,746 (1)(2)(5) Gusto, Series B-2, Acquisition Date: 8/18/20, Cost \$3,259 (1)(2)(5) Gusto, Series B-2, Acquisition Date: 8/18/20, Cost \$3,259 (1)(2)(5) Gusto, Series C, Acquisition Date: 7/16/18, Cost \$5,412 (2)(5) Gusto, Series D, Acquisition Date: 7/16/19, Cost \$7,227 (1)(2)(5) Mesosphere, Series D, Acquisition Date: 5/4/18, Cost \$13,430 (1) (2)(5) Nuro, Series C, Acquisition Date: 10/30/20 - 3/2/21, Cost \$11,195 (1)(2)(5) SecurityScorecard, Series E, Acquisition Date: 3/5/21, Cost \$9,505 (1)(2)(5) Socure, Series A, Acquisition Date: 12/22/21, Cost \$2,929 (1)(2) (5) Socure, Series B, Acquisition Date: 12/22/21, Cost \$2,404 (1) (2)(5) Socure, Series B, Acquisition Date: 12/22/21, Cost \$43 (1)(2)(5) Socure, Series B, Acquisition Date: 12/22/21, Cost \$43 (1)(2)(5) Socure, Series B, Acquisition Date: 12/22/21, Cost \$43 (1)(2)(5) Socure, Series E, Acquisition Date: 10/27/21, Cost \$5,572 (1)(2)(5) Socure, Series E, Acquisition Date: 10/27/21, Cost \$5,572 (1)(2)(5) Socure, Series E, Acquisition Date: 10/27/21, Cost \$5,572 (1)(2)(5) Socure, Series E, Acquisition Date: 10/27/21, Cost \$5,572 (1)(2)(5) Socure, Series E, Acquisition Date: 10/27/21, Cost \$5,572 (1)(2)(5) Socure, Series E, Acquisition Date: 10/27/21, Cost \$5,572 (1)(2)(5) Socure, Series E, Acquisition Date: 10/27/21, Cost \$5,572 (1)(2)(5) Socure, Series E, Acquisition Date: 10/27/21, Cost \$5,572 (1)(2)(5) Socure, Series E, Acquisition Date: 10/27/21, Cost \$5,572 (1)(2)(5) Socure, Series E, Acquisition Date: 10/27/21, Cost \$5,572 (1)(2)(5) Socure, Series E, Acquisition Date: 10/27/21, Cost \$5,572 (1)(2)(5)		3 030	5.1
Cost \$74 (1)(2)(5) Themis Solutions, Series E, Acquisition Date: 4/14/21, Cost \$8,658 (1)(2)(5) Software 0.5% Gusto, Series B, Acquisition Date: 8/18/20, Cost \$1,746 (1)(2)(5) Gusto, Series B-2, Acquisition Date: 8/18/20, Cost \$3,259 (1)(2)(5) Gusto, Series C, Acquisition Date: 8/18/20, Cost \$3,259 (1)(2)(5) Gusto, Series C, Acquisition Date: 7/16/18, Cost \$5,412 (2)(5) Gusto, Series D, Acquisition Date: 7/16/19, Cost \$7,227 (1)(2)(5) Mesosphere, Series D, Acquisition Date: 5/4/18, Cost \$13,430 (1) (2)(5) Nuro, Series C, Acquisition Date: 10/30/20 - 3/2/21, Cost \$11,195 (1)(2)(5) SecurityScorecard, Series E, Acquisition Date: 3/5/21, Cost \$9,505 (1)(2)(5) Socure, Series A, Acquisition Date: 12/22/21, Cost \$2,929 (1)(2) (5) Socure, Series B, Acquisition Date: 12/22/21, Cost \$2,929 (1)(2) (5) Socure, Series B, Acquisition Date: 12/22/21, Cost \$2,404 (1) (2)(5) Socure, Series B, Acquisition Date: 12/22/21, Cost \$43 (1)(2)(5) Socure, Series B, Acquisition Date: 10/27/21, Cost \$43 (1)(2)(5) Socure, Series E, Acquisition Date: 10/27/21, Cost \$43 (1)(2)(5) Socure, Series E, Acquisition Date: 10/27/21, Cost \$5,572 (1)(2)(5) Socure, Series E, Acquisition Date: 10/27/21, Cost \$5,572 (1)(2)(5) Socure, Series E, Acquisition Date: 10/27/21, Cost \$5,572 (1)(2)(5) Socure, Series E, Acquisition Date: 10/27/21, Cost \$5,572 (1)(2)(5) Socure, Series E, Acquisition Date: 10/27/21, Cost \$5,572 (1)(2)(5) Socure, Series E, Acquisition Date: 10/27/21, Cost \$5,572 (1)(2)(5) Socure, Series E, Acquisition Date: 10/27/21, Cost \$5,572 (1)(2)(5) Socure, Series E, Acquisition Date: 10/27/21, Cost \$5,572 (1)(2)(5) Socure, Series E, Acquisition Date: 10/27/21, Cost \$5,572 (1)(2)(5) Socure, Series E, Acquisition Date: 10/27/21, Cost \$5,572 (1)(2)(5)			
Cost \$8,658 (1)(2)(5) 385,620 6,872 Software 0.5% Gusto, Series B, Acquisition Date: 8/18/20, Cost \$1,746 (1)(2)(5) 129,187 2,433 Gusto, Series B-2, Acquisition Date: 8/18/20, Cost \$3,259 (1)(2)(5) 241,168 4,541 Gusto, Series C, Acquisition Date: 7/16/18, Cost \$5,412 (2)(5) 711,894 13,405 Gusto, Series D, Acquisition Date: 7/16/19, Cost \$7,227 (1)(2)(5) 542,859 10,222 Mesosphere, Series D, Acquisition Date: 5/4/18, Cost \$13,430 (1) (2)(5) 1,214,930 753 Nuro, Series C, Acquisition Date: 10/30/20 - 3/2/21, 20 857,551 5,317 Nuro, Series D, Acquisition Date: 10/29/21, Cost \$6,458 (1)(2)(5) 309,802 1,921 SecurityScorecard, Series E, Acquisition Date: 3/5/21, 1,881,753 9,597 Socure, Series A, Acquisition Date: 12/22/21, Cost \$2,929 (1)(2) 182,290 1,363 Socure, Series A-1, Acquisition Date: 12/22/21, Cost \$2,404 (1) 149,613 1,119 Socure, Series B, Acquisition Date: 12/22/21, Cost \$43 (1)(2)(5) 2,706 20 Socure, Series E, Acquisition Date: 10/27/21, Cost \$5,572 (1)(2)(5) 346,775		3,310	59
Software 0.5% Gusto, Series B, Acquisition Date: 8/18/20, Cost \$1,746 (1)(2)(5) 129,187 2,433 Gusto, Series B-2, Acquisition Date: 8/18/20, Cost \$3,259 (1)(2)(5) 241,168 4,541 Gusto, Series C, Acquisition Date: 7/16/18, Cost \$5,412 (2)(5) 711,894 13,405 Gusto, Series D, Acquisition Date: 7/16/19, Cost \$7,227 (1)(2)(5) 542,859 10,222 Mesosphere, Series D, Acquisition Date: 5/4/18, Cost \$13,430 (1) (2)(5) 1,214,930 753 Nuro, Series C, Acquisition Date: 10/30/20 - 3/2/21, Cost \$11,195 (1)(2)(5) 857,551 5,317 Nuro, Series D, Acquisition Date: 10/29/21, Cost \$6,458 (1)(2)(5) 309,802 1,921 SecurityScorecard, Series E, Acquisition Date: 3/5/21, Cost \$9,505 (1)(2)(5) 1,881,753 9,597 Socure, Series A, Acquisition Date: 12/22/21, Cost \$2,929 (1)(2) (5) 182,290 1,363 Socure, Series A-1, Acquisition Date: 12/22/21, Cost \$2,404 (1) (2)(5) 149,613 1,119 Socure, Series B, Acquisition Date: 12/22/21, Cost \$43 (1)(2)(5) 2,706 20 Socure, Series E, Acquisition Date: 10/27/21, Cost \$5,572 (1)(2)(5) 346,775 2,594 Socure, Series E, Acquisition Date: 10/27/21, Cost \$5,572 (1)(2)(5) 346,775 2,594	Themis Solutions, Series E, Acquisition Date: 4/14/21,		
Software 0.5% Gusto, Series B, Acquisition Date: 8/18/20, Cost \$1,746 (1)(2)(5) 129,187 2,433 Gusto, Series B-2, Acquisition Date: 8/18/20, Cost \$3,259 (1)(2)(5) 241,168 4,541 Gusto, Series C, Acquisition Date: 7/16/18, Cost \$5,412 (2)(5) 711,894 13,405 Gusto, Series D, Acquisition Date: 7/16/19, Cost \$7,227 (1)(2)(5) 542,859 10,222 Mesosphere, Series D, Acquisition Date: 5/4/18, Cost \$13,430 (1) (2)(5) 1,214,930 753 Nuro, Series C, Acquisition Date: 10/30/20 - 3/2/21, 857,551 5,317 Nuro, Series D, Acquisition Date: 10/29/21, Cost \$6,458 (1)(2)(5) 309,802 1,921 SecurityScorecard, Series E, Acquisition Date: 3/5/21, 1,881,753 9,597 Socure, Series A, Acquisition Date: 12/22/21, Cost \$2,929 (1)(2) 182,290 1,363 Socure, Series A-1, Acquisition Date: 12/22/21, Cost \$2,404 (1) 149,613 1,119 Socure, Series B, Acquisition Date: 12/22/21, Cost \$43 (1)(2)(5) 2,706 20 Socure, Series E, Acquisition Date: 10/27/21, Cost \$5,572 (1)(2)(5) 346,775 2,594 Socure, Series E, Acquisition Date: 10/27/21, Cost \$5,572 (1)(2)(5) 346,775 2,594	Cost \$8,658 (1)(2)(5)	385,620	6,872
Gusto, Series B, Acquisition Date: 8/18/20, Cost \$1,746 (1)(2)(5) 129,187 2,433 Gusto, Series B-2, Acquisition Date: 8/18/20, Cost \$3,259 (1)(2)(5) 241,168 4,541 Gusto, Series C, Acquisition Date: 7/16/18, Cost \$5,412 (2)(5) 711,894 13,405 Gusto, Series D, Acquisition Date: 7/16/19, Cost \$7,227 (1)(2)(5) 542,859 10,222 Mesosphere, Series D, Acquisition Date: 5/4/18, Cost \$13,430 (1) (2)(5) 1,214,930 753 Nuro, Series C, Acquisition Date: 10/30/20 - 3/2/21, 857,551 5,317 Nuro, Series D, Acquisition Date: 10/29/21, Cost \$6,458 (1)(2)(5) 309,802 1,921 SecurityScorecard, Series E, Acquisition Date: 3/5/21, 1,881,753 9,597 Socure, Series A, Acquisition Date: 12/22/21, Cost \$2,929 (1)(2) 182,290 1,363 Socure, Series A-1, Acquisition Date: 12/22/21, Cost \$2,404 (1) 149,613 1,119 Socure, Series B, Acquisition Date: 12/22/21, Cost \$43 (1)(2)(5) 2,706 20 Socure, Series E, Acquisition Date: 10/27/21, Cost \$5,572 (1)(2)(5) 346,775 2,594 Socure, Series E, Acquisition Date: 10/27/21, Cost \$5,572 (1)(2)(5) 346,775 2,594			7,528
Gusto, Series B-2, Acquisition Date: 8/18/20, Cost \$3,259 (1)(2)(5) 241,168 4,541 Gusto, Series C, Acquisition Date: 7/16/18, Cost \$5,412 (2)(5) 711,894 13,405 Gusto, Series D, Acquisition Date: 7/16/19, Cost \$7,227 (1)(2)(5) 542,859 10,222 Mesosphere, Series D, Acquisition Date: 5/4/18, Cost \$13,430 (1) (2)(5) 1,214,930 753 Nuro, Series C, Acquisition Date: 10/30/20 - 3/2/21, Cost \$11,195 (1)(2)(5) 857,551 5,317 Nuro, Series D, Acquisition Date: 10/29/21, Cost \$6,458 (1)(2)(5) 309,802 1,921 SecurityScorecard, Series E, Acquisition Date: 3/5/21, Cost \$9,505 (1)(2)(5) 1,881,753 9,597 Socure, Series A, Acquisition Date: 12/22/21, Cost \$2,929 (1)(2) (5) 182,290 1,363 Socure, Series A-1, Acquisition Date: 12/22/21, Cost \$2,404 (1) (2)(5) 149,613 1,119 Socure, Series B, Acquisition Date: 12/22/21, Cost \$43 (1)(2)(5) 2,706 20 Socure, Series E, Acquisition Date: 10/27/21, Cost \$5,572 (1)(2)(5) 346,775 2,594 53,285	Software 0.5%		
Gusto, Series C, Acquisition Date: 7/16/18, Cost \$5,412 (2)(5) 711,894 13,405 Gusto, Series D, Acquisition Date: 7/16/19, Cost \$7,227 (1)(2)(5) 542,859 10,222 Mesosphere, Series D, Acquisition Date: 5/4/18, Cost \$13,430 (1) (2)(5) 1,214,930 753 Nuro, Series C, Acquisition Date: 10/30/20 - 3/2/21, Cost \$11,195 (1)(2)(5) 857,551 5,317 Nuro, Series D, Acquisition Date: 10/29/21, Cost \$6,458 (1)(2)(5) 309,802 1,921 SecurityScorecard, Series E, Acquisition Date: 3/5/21, Cost \$9,505 (1)(2)(5) 1,881,753 9,597 Socure, Series A, Acquisition Date: 12/22/21, Cost \$2,929 (1)(2) (5) 182,290 1,363 Socure, Series A-1, Acquisition Date: 12/22/21, Cost \$2,404 (1) (2)(5) 149,613 1,119 Socure, Series B, Acquisition Date: 12/22/21, Cost \$43 (1)(2)(5) 2,706 20 Socure, Series E, Acquisition Date: 10/27/21, Cost \$5,572 (1)(2)(5) 346,775 2,594 53,285			
Gusto, Series D, Acquisition Date: 7/16/19, Cost \$7,227 (1)(2)(5) 542,859 10,222 Mesosphere, Series D, Acquisition Date: 5/4/18, Cost \$13,430 (1) 1,214,930 753 Nuro, Series C, Acquisition Date: 10/30/20 - 3/2/21, 857,551 5,317 Nuro, Series D, Acquisition Date: 10/29/21, Cost \$6,458 (1)(2)(5) 309,802 1,921 SecurityScorecard, Series E, Acquisition Date: 3/5/21, 309,802 1,921 Socure, Series A, Acquisition Date: 12/22/21, Cost \$2,929 (1)(2) 1,881,753 9,597 Socure, Series A, Acquisition Date: 12/22/21, Cost \$2,929 (1)(2) 182,290 1,363 Socure, Series A-1, Acquisition Date: 12/22/21, Cost \$2,404 (1) 149,613 1,119 Socure, Series B, Acquisition Date: 12/22/21, Cost \$43 (1)(2)(5) 2,706 20 Socure, Series E, Acquisition Date: 10/27/21, Cost \$5,572 (1)(2)(5) 346,775 2,594 53,285			
Mesosphere, Series D, Acquisition Date: 5/4/18, Cost \$13,430 (1) (2)(5) 1,214,930 753 Nuro, Series C, Acquisition Date: 10/30/20 - 3/2/21, Cost \$11,195 (1)(2)(5) 857,551 5,317 Nuro, Series D, Acquisition Date: 10/29/21, Cost \$6,458 (1)(2)(5) 309,802 1,921 SecurityScorecard, Series E, Acquisition Date: 3/5/21, Cost \$9,505 (1)(2)(5) 1,881,753 9,597 Socure, Series A, Acquisition Date: 12/22/21, Cost \$2,929 (1)(2) (5) 182,290 1,363 Socure, Series A-1, Acquisition Date: 12/22/21, Cost \$2,404 (1) (2)(5) 149,613 1,119 Socure, Series B, Acquisition Date: 12/22/21, Cost \$43 (1)(2)(5) 2,706 20 Socure, Series E, Acquisition Date: 10/27/21, Cost \$5,572 (1)(2)(5) 346,775 2,594			
(2)(5) 1,214,930 753 Nuro, Series C, Acquisition Date: 10/30/20 - 3/2/21, Cost \$11,195 (1)(2)(5) 857,551 5,317 Nuro, Series D, Acquisition Date: 10/29/21, Cost \$6,458 (1)(2)(5) 309,802 1,921 SecurityScorecard, Series E, Acquisition Date: 3/5/21, Cost \$9,505 (1)(2)(5) 1,881,753 9,597 Socure, Series A, Acquisition Date: 12/22/21, Cost \$2,929 (1)(2) (5) 182,290 1,363 Socure, Series A-1, Acquisition Date: 12/22/21, Cost \$2,404 (1) (2)(5) 149,613 1,119 Socure, Series B, Acquisition Date: 12/22/21, Cost \$43 (1)(2)(5) 2,706 20 Socure, Series E, Acquisition Date: 10/27/21, Cost \$5,572 (1)(2)(5) 346,775 2,594		542,859	10,222
Nuro, Series C, Acquisition Date: 10/30/20 - 3/2/21, Cost \$11,195 (1)(2)(5) 857,551 5,317 Nuro, Series D, Acquisition Date: 10/29/21, Cost \$6,458 (1)(2)(5) 309,802 1,921 SecurityScorecard, Series E, Acquisition Date: 3/5/21, Cost \$9,505 (1)(2)(5) 1,881,753 9,597 Socure, Series A, Acquisition Date: 12/22/21, Cost \$2,929 (1)(2) (5) 182,290 1,363 Socure, Series A-1, Acquisition Date: 12/22/21, Cost \$2,404 (1) (2)(5) 149,613 1,119 Socure, Series B, Acquisition Date: 12/22/21, Cost \$43 (1)(2)(5) 2,706 20 Socure, Series E, Acquisition Date: 10/27/21, Cost \$5,572 (1)(2)(5) 346,775 2,594		1.214.930	753
Cost \$11,195 (1)(2)(5) 857,551 5,317 Nuro, Series D, Acquisition Date: 10/29/21, Cost \$6,458 (1)(2)(5) 309,802 1,921 SecurityScorecard, Series E, Acquisition Date: 3/5/21, 1,881,753 9,597 Socure, Series A, Acquisition Date: 12/22/21, Cost \$2,929 (1)(2) 182,290 1,363 Socure, Series A-1, Acquisition Date: 12/22/21, Cost \$2,404 (1) 149,613 1,119 Socure, Series B, Acquisition Date: 12/22/21, Cost \$43 (1)(2)(5) 2,706 20 Socure, Series E, Acquisition Date: 10/27/21, Cost \$5,572 (1)(2)(5) 346,775 2,594 53,285			
SecurityScorecard, Series E, Acquisition Date: 3/5/21, 1,881,753 9,597 Cost \$9,505 (1)(2)(5) 1,881,753 9,597 Socure, Series A, Acquisition Date: 12/22/21, Cost \$2,929 (1)(2) 182,290 1,363 Socure, Series A-1, Acquisition Date: 12/22/21, Cost \$2,404 (1) 149,613 1,119 Socure, Series B, Acquisition Date: 12/22/21, Cost \$43 (1)(2)(5) 2,706 20 Socure, Series E, Acquisition Date: 10/27/21, Cost \$5,572 (1)(2)(5) 346,775 2,594 53,285		857,551	5,317
Cost \$9,505 (1)(2)(5) 1,881,753 9,597 Socure, Series A, Acquisition Date: 12/22/21, Cost \$2,929 (1)(2) 182,290 1,363 Socure, Series A-1, Acquisition Date: 12/22/21, Cost \$2,404 (1) 149,613 1,119 Socure, Series B, Acquisition Date: 12/22/21, Cost \$43 (1)(2)(5) 2,706 20 Socure, Series E, Acquisition Date: 10/27/21, Cost \$5,572 (1)(2)(5) 346,775 2,594 53,285		309,802	1,921
Socure, Series A, Acquisition Date: 12/22/21, Cost \$2,929 (1)(2) 182,290 1,363 Socure, Series A-1, Acquisition Date: 12/22/21, Cost \$2,404 (1) 149,613 1,119 Socure, Series B, Acquisition Date: 12/22/21, Cost \$43 (1)(2)(5) 2,706 20 Socure, Series E, Acquisition Date: 10/27/21, Cost \$5,572 (1)(2)(5) 346,775 2,594 53,285			
(5) 182,290 1,363 Socure, Series A-1, Acquisition Date: 12/22/21, Cost \$2,404 (1) (2)(5) 149,613 1,119 Socure, Series B, Acquisition Date: 12/22/21, Cost \$43 (1)(2)(5) 2,706 20 Socure, Series E, Acquisition Date: 10/27/21, Cost \$5,572 (1)(2)(5) 346,775 2,594 53,285		1,881,753	9,597
Socure, Series A-1, Acquisition Date: 12/22/21, Cost \$2,404 (1) 149,613 1,119 Socure, Series B, Acquisition Date: 12/22/21, Cost \$43 (1)(2)(5) 2,706 20 Socure, Series E, Acquisition Date: 10/27/21, Cost \$5,572 (1)(2)(5) 346,775 2,594 53,285		182 200	1 262
(2)(5) 149,613 1,119 Socure, Series B, Acquisition Date: 12/22/21, Cost \$43 (1)(2)(5) 2,706 20 Socure, Series E, Acquisition Date: 10/27/21, Cost \$5,572 (1)(2)(5) 346,775 2,594 53,285		102,290	
Socure, Series B, Acquisition Date: 12/22/21, Cost \$43 (1)(2)(5) 2,706 20 Socure, Series E, Acquisition Date: 10/27/21, Cost \$5,572 (1)(2)(5) 346,775 2,594 53,285		149,613	1,119
53,285			
	Socure, Series E, Acquisition Date: 10/27/21, Cost \$5,572 (1)(2)(5)	346,775	2,594
Total Information Technology 60,813			53,285
	Total Information Technology		60,813

	Shares/Par	\$ Value
(Cost and value in \$000s)		
MATERIALS 0.2%		
Chemicals 0.0%		
Sila Nano, Series F, Acquisition Date: 1/7/21, Cost \$11,381 (1)(2)		
(5)	275,749	
Madala 9 Minima O 00/		5,592
Metals & Mining 0.2%		
Kobold Metals, Series B-1, Acquisition Date: 1/10/22,	500 347	22,347
Cost \$14,318 (1)(2)(5)	322,047	22,347
Total Materiala		
Total Materials		27,939
Total Convertible Preferred Stocks (Cost \$370,202)		338,957
CORPORATE BONDS 0.1%		
PRA Group, 5.00%, 10/1/29 (8)	3,091,000	2.334
PRA Group, 7.375%, 9/1/25 (8)	7,228,000	
Total Corporate Bonds (Cost \$9,155)		9,200
PREFERRED STOCKS 0.0%		
ENERGY 0.0%		
Energy Equipment & Services 0.0%		
Energy Reservoir Holdings, Class A-3, Acquisition Date: 11/30/22,		
Cost \$144 (1)(2)(3)(5)	143,910	144
Energy Reservoir Holdings, Class A-3, Acquisition Date: 5/3/21 - 9/29/21, Cost \$1,287 (1)(2)(3)(5)(7)	1,286,870	1,364
- 9/29/21, Cost φ1,26/ (1)(2)(3)(3)(7) Total Energy		1,508
Total Preferred Stocks (Cost \$1,431)		1,508
10441110101104 0100110 (0001 \$1,101)		
SHORT-TERM INVESTMENTS 2.0%		
Money Market Funds 2.0%		
T. Rowe Price Government Reserve Fund, 5.13% (3)(9)	205,602,972	205,603
Total Short-Term Investments (Cost \$205,603)		205,603

Shares/Par

\$ Value

(Cost and value in \$000s)

SECURITIES LENDING COLLATERAL 0.4%

INVESTMENTS IN A POOLED ACCOUNT THROUGH SECURITIES LENDING PROGRAM WITH JPMORGAN CHASE **BANK 0.0%**

Money Market Funds 0.0%		
T. Rowe Price Government Reserve Fund, 5.13% (3)(9)	156,420	156
Total Investments in a Pooled Account through Securities Lending Program with JPMorgan Chase Bank		156
INVESTMENTS IN A POOLED ACCOUNT THROUGH SECURITIES LENDING PROGRAM WITH STATE STREET BANK AND TRUST COMPANY 0.4%		
Money Market Funds 0.4%		
T. Rowe Price Government Reserve Fund, 5.13% (3)(9)	40,204,442	40,205
Total Investments in a Pooled Account through Securities Lending Program with State Street Bank and Trust Company		40,205
Total Securities Lending Collateral (Cost \$40,361)		40,361
Total Investments in Securities 100.6% of Net Assets (Cost \$7,776,843)	¢	10.409.646
(ουσι ψι, ι ι ο,οπο)	Ψ	10,409,040

- ‡ Shares/Par are denominated in U.S. dollars unless otherwise noted.
- (1) Non-income producing
- (2) See Note 2. Level 3 in fair value hierarchy.
- (3) Affiliated Companies
- (4) See Note 3. All or a portion of this security is on loan at June 30, 2023.
- (5) Security cannot be offered for public resale without first being registered under the Securities Act of 1933 and related rules ("restricted security"). Acquisition date represents the day on which an enforceable right to acquire such security is obtained and is presented along with related cost in the security description. The fund may have registration rights for certain restricted securities. Any costs related to such registration are generally borne by the issuer. The aggregate value of restricted securities (excluding 144A holdings) at period end amounts to \$697,192 and represents 6.7% of net assets.
- (6) Security is subject to a contractual sale restriction (lockup). The total value of such securities at period-end amounts to \$132,444; the remaining lockup period is generally less than one year; and early lockup release provisions may be applicable based on certain set milestones or conditions in accordance with legal documents.
- (7) Investment in a partnership held indirectly through a limited liability company that is owned by the fund and treated as a corporation for U.S. tax purposes.

- (8) Security was purchased pursuant to Rule 144A under the Securities Act of 1933 and may be resold in transactions exempt from registration only to qualified institutional buyers. Total value of such securities at period-end amounts to \$9,200 and represents 0.1% of net assets.
- (9) Seven-day yield
- ADR American Depositary Receipts
- CAD Canadian Dollar
 - EC Escrow CUSIP; represents a beneficial interest in a residual pool of assets; the amount and timing of future distributions, if any, is uncertain; when presented, interest rate and maturity date are those of the original security.
- GBP British Pound
- REIT A domestic Real Estate Investment Trust whose distributions pass-through with original tax character to the shareholder

AFFILIATED COMPANIES

(\$000s)

The fund may invest in certain securities that are considered affiliated companies. As defined by the 1940 Act, an affiliated company is one in which the fund owns 5% or more of the outstanding voting securities, or a company that is under common ownership or control. The following securities were considered affiliated companies for all or some portion of the six months ended June 30, 2023. Net realized gain (loss), investment income, change in net unrealized gain/loss, and purchase and sales cost reflect all activity for the period then ended.

Affiliate	Net Realized Gain (Loss)	Change in Net Unrealized Gain/Loss	Investment Income
Boston Omaha, Class A	\$ 3,087 \$	(12,451)	\$
Clearwater Paper	126	(8,056)	_
Dogwood State Bank, Non-Voting Shares	_	585	_
Dogwood State Bank, Voting Shares	_	288	_
Dogwood State Bank, Warrants, 5/6/24	_	102	_
Energy Reservoir Holdings, Class A-1	_	(1)	_
Energy Reservoir Holdings, Class A-3	_	_	_
Energy Reservoir Holdings, Class A-3	_	_	_
FS Bancorp	49	(2,060)	317
James River Group Holdings	6	(5,625)	553
John Marshall Bancorp	41	(8,595)	233
Live Oak Bancshares	144	(9,778)	149
Metropolitan Bank Holding	13	(11,762)	_
Myers Industries	1,200	(5,589)	469
National Bank Holdings, Class A	149	(25,332)	985
Preferred Bank	174	(12,567)	793
Ranger Energy Services	(1,262)	67	_
RGC Resources	(981)	21	224
Saul Centers, REIT	81	(3,848)	3,904
Southern First Bancshares	17	(9,568)	_
Strategic Education	(53)	(12,044)	1,426
Strattec Security	(98)	(711)	_
Tonian Holdings, Series A, Non-Voting Shares	_	1	_
Tonian Holdings, Series A, Voting Shares	_	_	_
Triumph Group	(50,120)	55,599	_
Utah Medical Products	(124)	(1,591)	142
T. Rowe Price Government Reserve Fund, 5.13%	_	_	4,347++
Affiliates not held at period end	 (46,366)	93,340	
Totals	\$ (93,917)# \$	20,425	\$ 13,542+

AFFILIATED COMPANIES (CONTINUED)

(\$000s)

	Value	Purchase	Sales	Value
Affiliate	12/31/22	Cost	Cost	06/30/23
AgroFresh Solutions \$	15,110 \$	- \$	30,268 \$	_
American Public Education	13,349	_	26,556	_
Boston Omaha, Class A	46,970	47	23,403	*
CIRCOR International	39,650	56	51,973	_
Clearwater Paper	38,800	9,214	26	39,932
Dogwood State Bank, Non-				
Voting Shares	*	_	_	5,847
Dogwood State Bank, Voting	*			0.070
Shares		_	_	2,872
Dogwood State Bank, Warrants,	*			454
5/6/24		_	_	454
Energy Reservoir Holdings, Class A-1	9,394			9,393
Energy Reservoir Holdings,	9,394	_	_	9,393
Class A-3	144			144
Energy Reservoir Holdings,	144	_	_	144
Class A-3	1,364	_	_	1,364
FS Bancorp	19,136	3,126	32	20,170
Horizon Global	1,255	-	23,858	
James River Group Holdings	47,754	93	593	41,629
John Marshall Bancorp	28,820	1,065	51	21,239
Live Oak Bancshares	75,105	129	133	65,323
LL Flooring Holdings	12,969	_	38,766	_
Metropolitan Bank Holding	*	7,059	81	19,331
Myers Industries	45,660	72	6,440	*
National Bank Holdings, Class	,	. –	2, 112	
Α	80,117	2,188	137	56,836
Preferred Bank	53,839	9,353	23	50,602
Ranger Energy Services	29,835	63	12,620	17,345
RGC Resources	12,676	19	7,319	*
Saul Centers, REIT	54,068	97	1,454	48,863
Southern First Bancshares	20,845	24	47	11,254
Strategic Education	95,042	1,338	3,755	*
Strattec Security	7,164	14	374	6,093
Tonian Holdings, Series A, Non-	•			,
Voting Shares	10,237	_	_	10,238
Tonian Holdings, Series A,				
Voting Shares	18,060	_	_	18,060
Triumph Group	58,424	115	85,272	*

AFFILIATED COMPANIES (CONTINUED)

(\$000s)

		Value	Purchase	•	Sales		Value	
Affiliate		12/31/22	Cost		Cost		06/30/23	
Triumph Group, Warrants,								
12/19/23, 12.35%	\$	1,116 \$	_	\$	_	\$	_	
U.S. Xpress Enterprises, Class	3							
A		3,467	1		8,892		_	
Utah Medical Products		24,250	318		986		21,991	
T. Rowe Price Government								
Reserve Fund, 5.13%		267,249	¤		۵		245,964	
Total						\$	714,944^	

- # Capital gain distributions from underlying Price funds represented \$0 of the net realized gain (loss).
- ++ Excludes earnings on securities lending collateral, which are subject to rebates and fees as described in Note 3.
- + Investment income comprised \$13,542 of dividend income and \$0 of interest income.
- Purchase and sale information not shown for cash management funds.
- ^ The cost basis of investments in affiliated companies was \$683,256.
- * On the date indicated, issuer was held but not considered an affiliated company.

June 30, 2023 (Unaudited)

STATEMENT OF ASSETS AND LIABILITIES

(\$000s, except shares and per share amounts)

Assets	
Investments in securities, at value (cost \$7,776,843)	\$ 10,409,646
Receivable for investment securities sold	21,590
Dividends and interest receivable	7,206
Receivable for shares sold	6,667
Cash	3,728
Due from affiliates	1,243
Other assets	117
Total assets	10,450,197
Liabilities	
Payable for investment securities purchased	51,334
Obligation to return securities lending collateral	40,361
Payable for shares redeemed	9,513
Investment management fees payable	5,320
Payable to directors	9
Other liabilities	1,190
Total liabilities	107,727
NET ASSETS	\$ 10,342,470

June 30, 2023 (Unaudited)

STATEMENT OF ASSETS AND LIABILITIES

(\$000s, except shares and per share amounts)

Net Assets Consist of: Total distributable earnings (loss)	\$	2,828,239
Paid-in capital applicable to 207,819,792 shares of \$0.01 par value capital stock outstanding; 1,000,000,000 shares		
authorized		7,514,231
NET ASSETS	\$	10,342,470
NET ASSET VALUE PER SHARE		
Investor Class		
(Net assets: \$4,502,607; Shares outstanding: 90,552,365) Advisor Class	<u>\$</u>	49.72
(Net assets: \$77,256; Shares outstanding: 1,560,238) I Class	\$	49.52
(Net assets: \$2,930,854; Shares outstanding: 59,036,234) Z Class	\$	49.65
(Net assets: \$2,831,753; Shares outstanding: 56,670,955)	\$	49.97

STATEMENT OF OPERATIONS

(\$000s)

		6 Months Ended 6/30/23
Investment Income (Loss)		
Income		
Dividend (net of foreign taxes of \$324)		\$ 77,501
Securities lending		165
Interest		65
Other		47
Total income		 77,778
Expenses		
Investment management		32,790
Shareholder servicing		
Investor Class	\$ 2,962	
Advisor Class	37	
I Class	 228	 3,227
Rule 12b-1 fees		
Advisor Class		95
Prospectus and shareholder reports		
Investor Class	180	
Advisor Class	8	
I Class	74	
Z Class	 1	 263
Proxy and annual meeting		183
Custody and accounting		180
Registration		72
Legal and audit		26
Directors		19
Waived / paid by Price Associates		(8,952)
Total expenses		 27,903
Net investment income		 49,875

STATEMENT OF OPERATIONS

(\$000s)

	6 Months Ended 6/30/23
Realized and Unrealized Gain / Loss	
Net realized gain (loss)	
Securities	90,181
Foreign currency transactions	2
Net realized gain	 90,183
Change in net unrealized gain / loss	
Securities	253,397
Other assets and liabilities denominated in foreign currencies	 2
Change in net unrealized gain / loss	 253,399
Net realized and unrealized gain / loss	 343,582
INCREASE IN NET ASSETS FROM OPERATIONS	\$ 393,457

The accompanying notes are an integral part of these financial statements.

STATEMENT OF CHANGES IN NET ASSETS

(\$000s)

Increase (Decrease) in Net Assets	6 Month Ende 6/30/2	d	Year Ended 12/31/22
Operations			
Net investment income	\$ 49,87	5 \$	73,447
Net realized gain	90,18	3	809,310
Change in net unrealized gain / loss	253,39	9	(3,421,966)
Increase (decrease) in net assets from operations	393,45	7	(2,539,209)
Distributions to shareholders			
Net earnings			
Investor Class		-	(231,723)
Advisor Class		-	(3,628)
I Class		-	(154,288)
Z Class		-	(162,217)
Decrease in net assets from distributions		-	(551,856)
Capital share transactions*			
Shares sold			
Investor Class	303,87	9	855,839
Advisor Class	4,75	2	15,905
I Class	175,65	1	1,825,520
Z Class	103,05	9	177,054
Distributions reinvested			
Investor Class		-	224,458
Advisor Class		-	3,559
I Class		-	141,442
Z Class		-	162,217
Shares redeemed			
Investor Class	(532,009))	(2,719,623)
Advisor Class	(7,316	3)	(23,284)
I Class	(253,249	∌)	(768,152)
Z Class	(141,769))	(768,514)
Decrease in net assets from capital share transactions	(347,002	2)	(873,579)
			37

STATEMENT OF CHANGES IN NET ASSETS

(\$000s)

	6 Months Ended 6/30/23	Year Ended 12/31/22
Net Assets		
Increase (decrease) during period	46,455	(3,964,644)
Beginning of period	10,296,015	14,260,659
End of period	\$ 10,342,470	\$ 10,296,015
*Share information (000s)		
Shares sold		
Investor Class	6,213	15,693
Advisor Class	96	285
I Class	3,581	33,178
Z Class	2,106	3,238
Distributions reinvested		
Investor Class	_	4,501
Advisor Class	-	72
I Class	-	2,843
Z Class	-	3,251
Shares redeemed		
Investor Class	(10,950)	(49,879)
Advisor Class	(151)	(440)
I Class	(5,216)	(14,034)
Z Class	(2,875)	(14,440)
Decrease in shares outstanding	(7,196)	(15,732)

Unaudited

NOTES TO FINANCIAL STATEMENTS

T. Rowe Price Small-Cap Value Fund, Inc. (the fund) is registered under the Investment Company Act of 1940 (the 1940 Act) as a diversified, open-end management investment company. The fund seeks long-term capital growth by investing primarily in small companies whose common stocks are believed to be undervalued. The fund has four classes of shares: the Small-Cap Value Fund (Investor Class), the Small-Cap Value Fund-Advisor Class (Advisor Class), the Small-Cap Value Fund-I Class (I Class) and the Small-Cap Value Fund-Z Class (Z Class). Advisor Class shares are sold only through various brokers and other financial intermediaries. I Class shares require a \$500,000 initial investment minimum, although the minimum generally is waived or reduced for financial intermediaries, eligible retirement plans, and certain other accounts. The Z Class is only available to funds advised by T. Rowe Price Associates, Inc. and its affiliates and other clients that are subject to a contractual fee for investment management services. The Advisor Class operates under a Board-approved Rule 12b-1 plan pursuant to which the class compensates financial intermediaries for distribution, shareholder servicing, and/or certain administrative services; the Investor, I and Z Classes do not pay Rule 12b-1 fees. Each class has exclusive voting rights on matters related solely to that class; separate voting rights on matters that relate to all classes; and, in all other respects, the same rights and obligations as the other classes.

NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES

Basis of Preparation The fund is an investment company and follows accounting and reporting guidance in the Financial Accounting Standards Board (FASB) Accounting Standards Codification Topic 946 (ASC 946). The accompanying financial statements were prepared in accordance with accounting principles generally accepted in the United States of America (GAAP), including, but not limited to, ASC 946. GAAP requires the use of estimates made by management. Management believes that estimates and valuations are appropriate; however, actual results may differ from those estimates, and the valuations reflected in the accompanying financial statements may differ from the value ultimately realized upon sale or maturity.

Investment Transactions, Investment Income, and Distributions Investment transactions are accounted for on the trade date basis. Income and expenses are recorded on the accrual basis. Realized gains and losses are reported on the identified cost basis. Income tax-related interest and penalties, if incurred, are recorded as income tax expense. Dividends received from other investment companies are reflected as dividend income; capital gain distributions are reflected as realized gain/loss.

Dividend income and capital gain distributions are recorded on the ex-dividend date. Distributions from REITs are initially recorded as dividend income and, to the extent such represent a return of capital or capital gain for tax purposes, are reclassified when such information becomes available. Non-cash dividends, if any, are recorded at the fair market value of the asset received. Proceeds from litigation payments, if any, are included in either net realized gain (loss) or change in net unrealized gain/loss from securities. Distributions to shareholders are recorded on the ex-dividend date. Income distributions, if any, are declared and paid by each class annually. A capital gain distribution, if any, may also be declared and paid by the fund annually.

Currency Translation Assets, including investments, and liabilities denominated in foreign currencies are translated into U.S. dollar values each day at the prevailing exchange rate, using the mean of the bid and asked prices of such currencies against U.S. dollars as provided by an outside pricing service. Purchases and sales of securities, income, and expenses are translated into U.S. dollars at the prevailing exchange rate on the respective date of such transaction. The effect of changes in foreign currency exchange rates on realized and unrealized security gains and losses is not bifurcated from the portion attributable to changes in market prices.

Class Accounting Shareholder servicing, prospectus, and shareholder report expenses incurred by each class are charged directly to the class to which they relate. Expenses common to all classes, investment income, and realized and unrealized gains and losses are allocated to the classes based upon the relative daily net assets of each class. The Advisor Class pays Rule 12b-1 fees, in an amount not exceeding 0.25% of the class's average daily net assets.

In-Kind Redemptions In accordance with guidelines described in the fund's prospectus, and when considered to be in the best interest of all shareholders, the fund may distribute portfolio securities rather than cash as payment for a redemption of fund shares (in-kind redemption). Gains and losses realized on in-kind redemptions are not recognized for tax purposes and are reclassified from undistributed realized gain (loss) to paid-in capital. During the six months ended June 30, 2023, the fund realized \$18,388,000 of net gain on \$36,829,000 of in-kind redemptions.

In-Kind Subscriptions Under certain circumstances, and when considered to be in the best interest of all shareholders, the fund may accept portfolio securities rather than cash as payment for the purchase of fund shares (in-kind subscription). For financial reporting and tax purposes, the cost basis of contributed securities is equal to the market value of the securities on the date of contribution. In-kind subscriptions result in no

gain or loss and no tax consequences for the fund. During the six months ended June 30, 2023, the fund accepted \$20,192,000 of in-kind subscriptions, all of which were from other T. Rowe Price funds.

Capital Transactions Each investor's interest in the net assets of the fund is represented by fund shares. The fund's net asset value (NAV) per share is computed at the close of the New York Stock Exchange (NYSE), normally 4 p.m. ET, each day the NYSE is open for business. However, the NAV per share may be calculated at a time other than the normal close of the NYSE if trading on the NYSE is restricted, if the NYSE closes earlier, or as may be permitted by the SEC. Purchases and redemptions of fund shares are transacted at the next-computed NAV per share, after receipt of the transaction order by T. Rowe Price Associates, Inc., or its agents.

New Accounting Guidance In June 2022, the FASB issued Accounting Standards Update (ASU), ASU 2022-03, Fair Value Measurement (Topic 820) – Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions, which clarifies that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. The amendments under this ASU are effective for fiscal years beginning after December 15, 2023; however, the fund opted to early adopt, as permitted, effective December 1, 2022. Adoption of the guidance did not have a material impact on the fund's financial statements.

The FASB issued Accounting Standards Update (ASU), ASU 2020–04, Reference Rate Reform (Topic 848) – Facilitation of the Effects of Reference Rate Reform on Financial Reporting in March 2020 and ASU 2021-01 in January 2021 which provided further amendments and clarifications to Topic 848. These ASUs provide optional, temporary relief with respect to the financial reporting of contracts subject to certain types of modifications due to the planned discontinuation of the London Interbank Offered Rate (LIBOR), and other interbank-offered based reference rates, through December 31, 2022. In December 2022, FASB issued ASU 2022-06 which defers the sunset date of Topic 848 from December 31, 2022 to December 31, 2024, after which entities will no longer be permitted to apply the relief in Topic 848. Management intends to rely upon the relief provided under Topic 848, which is not expected to have a material impact on the fund's financial statements.

Indemnification In the normal course of business, the fund may provide indemnification in connection with its officers and directors, service providers, and/or private company investments. The fund's maximum exposure under these arrangements is unknown; however, the risk of material loss is currently considered to be remote.

NOTE 2 - VALUATION

Fair Value The fund's financial instruments are valued at the close of the NYSE and are reported at fair value, which GAAP defines as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fund's Board of Directors (the Board) has designated T. Rowe Price Associates, Inc. as the fund's valuation designee (Valuation Designee). Subject to oversight by the Board, the Valuation Designee performs the following functions in performing fair value determinations: assesses and manages valuation risks; establishes and applies fair value methodologies; tests fair value methodologies; and evaluates pricing vendors and pricing agents. The duties and responsibilities of the Valuation Designee are performed by its Valuation Committee. The Valuation Designee provides periodic reporting to the Board on valuation matters.

Various valuation techniques and inputs are used to determine the fair value of financial instruments. GAAP establishes the following fair value hierarchy that categorizes the inputs used to measure fair value:

- Level 1 quoted prices (unadjusted) in active markets for identical financial instruments that the fund can access at the reporting date
- Level 2 inputs other than Level 1 quoted prices that are observable, either directly or indirectly (including, but not limited to, quoted prices for similar financial instruments in active markets, quoted prices for identical or similar financial instruments in inactive markets, interest rates and yield curves, implied volatilities, and credit spreads)
- Level 3 unobservable inputs (including the Valuation Designee's assumptions in determining fair value)

Observable inputs are developed using market data, such as publicly available information about actual events or transactions, and reflect the assumptions that market participants would use to price the financial instrument. Unobservable inputs are those for which market data are not available and are developed using the best information available about the assumptions that market participants would use to price the financial instrument. GAAP requires valuation techniques to maximize the use of relevant observable inputs and minimize the use of unobservable inputs. When multiple inputs are used to derive fair value, the financial instrument is assigned to the level within the fair value hierarchy based on the lowest-level input that is significant to the fair value of the financial instrument. Input levels are not necessarily an indication of the risk or liquidity associated with financial instruments at that level but rather the degree of judgment used in determining those values.

Valuation Techniques Equity securities, including exchange-traded funds, listed or regularly traded on a securities exchange or in the over-the-counter (OTC) market are valued at the last quoted sale price or, for certain markets, the official closing price at the time the valuations are made. OTC Bulletin Board securities are valued at the mean of the closing bid and asked prices. A security that is listed or traded on more than one exchange is valued at the quotation on the exchange determined to be the primary market for such security. Listed securities not traded on a particular day are valued at the mean of the closing bid and asked prices for domestic securities and the last quoted sale or closing price for international securities.

The last quoted prices of non-U.S. equity securities may be adjusted to reflect the fair value of such securities at the close of the NYSE, if the Valuation Designee determines that developments between the close of a foreign market and the close of the NYSE will affect the value of some or all of the fund's portfolio securities. Each business day, the Valuation Designee uses information from outside pricing services to evaluate the quoted prices of portfolio securities and, if appropriate, decide whether it is necessary to adjust quoted prices to reflect fair value by reviewing a variety of factors, including developments in foreign markets, the performance of U.S. securities markets, and the performance of instruments trading in U.S. markets that represent foreign securities and baskets of foreign securities. The Valuation Designee uses outside pricing services to provide it with quoted prices and information to evaluate or adjust those prices. The Valuation Designee cannot predict how often it will use quoted prices and how often it will determine it necessary to adjust those prices to reflect fair value.

Debt securities generally are traded in the over-the-counter (OTC) market and are valued at prices furnished by independent pricing services or by broker dealers who make markets in such securities. When valuing securities, the independent pricing services consider factors such as, but not limited to, the yield or price of bonds of comparable quality, coupon, maturity, and type, as well as prices quoted by dealers who make markets in such securities.

Investments in mutual funds are valued at the mutual fund's closing NAV per share on the day of valuation. Assets and liabilities other than financial instruments, including short-term receivables and payables, are carried at cost, or estimated realizable value, if less, which approximates fair value.

Investments for which market quotations are not readily available or deemed unreliable are valued at fair value as determined in good faith by the Valuation Designee. The Valuation Designee has adopted methodologies for determining the fair value of investments for which market quotations are not readily available or deemed unreliable, including the use of other pricing sources. Factors used in determining fair value vary

by type of investment and may include market or investment specific considerations. The Valuation Designee typically will afford greatest weight to actual prices in arm's length transactions, to the extent they represent orderly transactions between market participants, transaction information can be reliably obtained, and prices are deemed representative of fair value. However, the Valuation Designee may also consider other valuation methods such as market-based valuation multiples; a discount or premium from market value of a similar, freely traded security of the same issuer; discounted cash flows; yield to maturity; or some combination. Fair value determinations are reviewed on a regular basis. Because any fair value determination involves a significant amount of judgment, there is a degree of subjectivity inherent in such pricing decisions. Fair value prices determined by the Valuation Designee could differ from those of other market participants, and it is possible that the fair value determined for a security may be materially different from the value that could be realized upon the sale of that security.

Valuation Inputs The following table summarizes the fund's financial instruments, based on the inputs used to determine their fair values on June 30, 2023 (for further detail by category, please refer to the accompanying Portfolio of Investments):

(\$000s)	Level 1	Level 2	Level 3	Total Value
Assets				
Corporate Bonds	\$ - \$	9,200	\$ -	\$ 9,200
Common Stocks	9,358,834	230,900	223,686	9,813,420
Convertible Bonds	_	_	597	597
Convertible Preferred Stocks	_	_	338,957	338,957
Preferred Stocks	_	_	1,508	1,508
Short-Term Investments	205,603	_	_	205,603
Securities Lending Collateral	40,361	_	_	40,361
Total	\$ 9,604,798 \$	240,100	\$ 564,748	\$ 10,409,646

Following is a reconciliation of the fund's Level 3 holdings for the six months ended June 30, 2023. Gain (loss) reflects both realized and change in unrealized gain/loss on Level 3 holdings during the period, if any, and is included on the accompanying Statement of Operations. The change in unrealized gain/loss on Level 3 instruments held at June 30, 2023, totaled \$(35,930,000) for the six months ended June 30, 2023.

(\$000s)	Beginning Balance 12/31/22	ain (Loss) During Period	Pur	Total chases	Tota	l Sales	Ending Balance 6/30/23
Investment in Securities							
Common Stocks	\$ 212,364	\$ 15,707	\$	_	\$	(4,385)	\$ 223,686
Convertible Bonds	_	_		597		_	597
Convertible Preferred Stocks	422,052	(54,199)		3,065	(3	31,961)	338,957
Preferred Stocks	1,508	_		_		_	1,508
			•	*			
Total	\$ 635,924	\$ (38,492)	\$	3,662	\$ (3	86,346)	\$ 564,748

In accordance with GAAP, the following table provides quantitative information about significant unobservable inputs used to determine the fair valuations of the fund's Level 3 assets, by class of financial instrument. Because the Valuation Designee considers a wide variety of factors and inputs, both observable and unobservable, in determining fair values, the unobservable inputs presented do not reflect all inputs significant to the fair value determination.

Investments in Securities	Value (000s)	Valuation Technique(s)+	Significant Unobservable Input(s)	Range of	Weighted Average of Input(s)*	Impact to Valuation from an Increase in Input**
Common Stocks	\$223,686	Recent comparable transaction price(s)	-#	 #	-#	-#
			Discount for uncertainty	100%	100%	Decrease
		Expected present value	Discount rate for cost of equity	11%	11%	Decrease
			Discount for lack of collectability	50%	50%	Decrease
			Timing of events	2.08 yrs	2.08 yrs	Decrease
		Market comparable	Probability for potential outcome	25% - 40%	33%	Increase
			Discount for liquidation preference	-#	-#	Increase
			Enterprise value to sales multiple	1.9x - 14.3x	4.5x	Increase
			Sales growth rate	15% - 168%	26%	Increase
			Enterprise value to gross profit multiple	3.8x - 18.4x	8.3x	Increase

Investments in Securities	Value (000s)	Valuation Technique(s)+	Significant Unobservable Input(s)		Weighted Average of Input(s)*	Impact to Valuation from an Increase in Input**
			Gross profit growth rate	11% - 50%	23%	Increase
			Enterprise value to EBITDA multiple	16.5x - 19.3x	17.6x	Increase
			EBITDA growth rate	125%	125%	Increase
			Price to tangible book value multiple	0.8x - 0.9x	0.9x	Increase
			Tangible book value growth rate	14%	14%	Increase
			Price-to- earnings multiple	8.4x - 11.9x	10.3x	Increase
			Price-to- earnings growth rate	0% - 85%	43%	Increase
			Discount for lack of collectability	100%	100%	Decrease
			Discount for lack of marketability	10%	10%	Decrease
		Options Pricing Model	Private company valuation	-#	-#	-#
			Risk-free rate	4%	4%	Increase
			Volatility	37% - 39%	37%	Increase
Convertible Bonds	\$597	Recent comparable transaction price(s)	-#	-#	-#	-#

Investments in Securities	Value (000s)	Valuation Technique(s)+	Significant Unobservable Input(s)		Weighted Average of Input(s)*	Impact to Valuation from an Increase in Input**
Convertible Preferred Stocks	\$338,957	Recent comparable transaction price(s)	- #	- #	— #	- #
		Market Comparable	Probability for potential outcome	25% - 40%	33%	Increase
			Premium for liquidation preference	-#	-#	Increase
			Enterprise value to sales multiple	0.8x - 14.3x	4.7x	Increase
			Sales growth rate	1% - 172%	43%	Increase
			Enterprise value to gross profit multiple	1.9x - 18.4x	9.6x	Increase
			Gross profit growth rate	8% - 50%	35%	Increase
			Enterprise value to EBITDA multiple	7.5x - 19.3x	9.6x	Increase
			EBITDA growth rate	65%	65%	Increase
			Enterprise value to gross merchandise value multiple	0.5x - 0.6x	0.6x	Increase
			Gross merchandise value growth rate	30%	30%	Increase

Investments in Securities	Value (000s)	Valuation Technique(s)+	Significant Unobservable Input(s)		Weighted Average of Input(s)*	Impact to Valuation from an Increase in Input**
			Projected enterprise value to sales multiple	0.8x - 5.1x	3.5x	Increase
			Projected enterprise value to EBITDA multiple	15.1x	15.1x	Increase
			Price-to- earnings multiple	8.4x - 11.9x	10.3x	Increase
			Price-to- earnings growth rate	0% - 85%	43%	Increase
			Discount rate for cost of capital	20% - 40%	29%	Decrease
			Discount for uncertainty	70%	70%	Decrease
			Discount for lack of collectability	100%	100%	Decrease
			Discount for lack of marketability	10%	10%	Decrease
		Estimated liquidation value	Discount for lack of collectability	100%	100%	Decrease
Preferred Stocks	\$1,508	Recent comparable transaction price(s)	-#	-#	-#	- #

Investments in Securities	Value (000s)	Valuation Technique(s)+	Significant Unobservable Input(s)	Range of	Weighted Average of Input(s)*	Impact to Valuation from an Increase in Input**
			Discount for uncertainty	5%	5%	Decrease

- Valuation techniques may change in order to reflect the Valuation Designee's judgment of current market participant assumptions.
- * Unobservable inputs were weighted by the relative fair value of the instruments.
- **Represents the directional change in the fair value of the Level 3 investment(s) that would have resulted from an increase in the corresponding input at period end. A decrease in the unobservable input would have had the opposite effect. Significant increases and decreases in these inputs in isolation could result in significantly higher or lower fair value measurements.
- # No quantitative unobservable inputs significant to the valuation technique were created by the Valuation Designee.

NOTE 3 - OTHER INVESTMENT TRANSACTIONS

Consistent with its investment objective, the fund engages in the following practices to manage exposure to certain risks and/or to enhance performance. The investment objective, policies, program, and risk factors of the fund are described more fully in the fund's prospectus and Statement of Additional Information.

Restricted Securities The fund invests in securities that are subject to legal or contractual restrictions on resale. Prompt sale of such securities at an acceptable price may be difficult and may involve substantial delays and additional costs.

Securities Lending The fund may lend its securities to approved borrowers to earn additional income. Its securities lending activities are administered by a lending agent in accordance with a securities lending agreement. Security loans generally do not have stated maturity dates, and the fund may recall a security at any time. The fund receives collateral in the form of cash or U.S. government securities. Collateral is maintained over the life of the loan in an amount not less than the value of loaned securities; any additional collateral required due to changes in security values is delivered to the fund the next business day. Cash collateral is invested in accordance with investment guidelines approved by fund management. Additionally, the lending agent indemnifies the fund against losses resulting from borrower default. Although risk is mitigated by the collateral and indemnification, the fund could experience a delay in recovering its securities and a possible loss of income or value if the borrower fails to return the

securities, collateral investments decline in value, and the lending agent fails to perform. Securities lending revenue consists of earnings on invested collateral and borrowing fees, net of any rebates to the borrower, compensation to the lending agent, and other administrative costs. In accordance with GAAP, investments made with cash collateral are reflected in the accompanying financial statements, but collateral received in the form of securities is not. At June 30, 2023, the value of loaned securities was \$39,296,000; the value of cash collateral and related investments was \$40,361,000.

Other Purchases and sales of portfolio securities other than short-term securities aggregated \$1,415,478,000 and \$1,661,850,000, respectively, for the six months ended June 30, 2023.

NOTE 4 - FEDERAL INCOME TAXES

Generally, no provision for federal income taxes is required since the fund intends to continue to qualify as a regulated investment company under Subchapter M of the Internal Revenue Code and distribute to shareholders all of its taxable income and gains. Distributions determined in accordance with federal income tax regulations may differ in amount or character from net investment income and realized gains for financial reporting purposes. Financial reporting records are adjusted for permanent book/ tax differences to reflect tax character but are not adjusted for temporary differences. The amount and character of tax-basis distributions and composition of net assets are finalized at fiscal year-end; accordingly, tax-basis balances have not been determined as of the date of this report.

At June 30, 2023, the cost of investments (including derivatives, if any) for federal income tax purposes was \$7,807,785,000. Net unrealized gain aggregated \$2,601,863,000 at period-end, of which \$3,418,042,000 related to appreciated investments and \$816,179,000 related to depreciated investments.

NOTE 5 - FOREIGN TAXES

The fund is subject to foreign income taxes imposed by certain countries in which it invests. Additionally, capital gains realized upon disposition of securities issued in or by certain foreign countries are subject to capital gains tax imposed by those countries. All taxes are computed in accordance with the applicable foreign tax law, and, to the extent permitted, capital losses are used to offset capital gains. Taxes attributable to income are accrued by the fund as a reduction of income. Current and deferred tax expense attributable to capital gains is reflected as a component of realized or change

in unrealized gain/loss on securities in the accompanying financial statements. To the extent that the fund has country specific capital loss carryforwards, such carryforwards are applied against net unrealized gains when determining the deferred tax liability. Any deferred tax liability incurred by the fund is included in either Other liabilities or Deferred tax liability on the accompanying Statement of Assets and Liabilities.

NOTE 6 - RELATED PARTY TRANSACTIONS

The fund is managed by T. Rowe Price Associates, Inc. (Price Associates), a wholly owned subsidiary of T. Rowe Price Group, Inc. (Price Group). Price Associates has entered into a sub-advisory agreement(s) with one or more of its wholly owned subsidiaries, to provide investment advisory services to the fund. The investment management agreement between the fund and Price Associates provides for an annual investment management fee, which is computed daily and paid monthly. The fee consists of an individual fund fee, equal to 0.35% of the fund's average daily net assets, and a group fee. The group fee rate is calculated based on the combined net assets of certain mutual funds sponsored by Price Associates (the group) applied to a graduated fee schedule, with rates ranging from 0.48% for the first \$1 billion of assets to 0.260% for assets in excess of \$845 billion. The fund's group fee is determined by applying the group fee rate to the fund's average daily net assets. At June 30, 2023, the effective annual group fee rate was 0.29%.

Effective June 1, 2023, the Advisor Class is subject to a contractual expense limitation through the expense limitation date indicated in the table below. During the limitation period, Price Associates is required to waive its management fee or pay any expenses (excluding interest; expenses related to borrowings, taxes, and brokerage; non-recurring, extraordinary expenses; and acquired fund fees and expenses) that would otherwise cause the class's ratio of annualized total expenses to average net assets (net expense ratio) to exceed its expense limitation. The class is required to repay Price Associates for expenses previously waived/paid to the extent the class's net assets grow or expenses decline sufficiently to allow repayment without causing the class's net expense ratio (after the repayment is taken into account) to exceed the lesser of: (1) the expense limitation in place at the time such amounts were waived; or (2) the class's current expense limitation. However, no repayment will be made more than three years after the date of a payment or waiver.

The I Class is also subject to an operating expense limitation (I Class Limit) pursuant to which Price Associates is contractually required to pay all operating expenses of the I Class, excluding management fees; interest; expenses related to borrowings, taxes, and brokerage; non-recurring, extraordinary expenses; and acquired fund fees

and expenses, to the extent such operating expenses, on an annualized basis, exceed the I Class Limit. This agreement will continue through the expense limitation date indicated in the table below, and may be renewed, revised, or revoked only with approval of the fund's Board. The I Class is required to repay Price Associates for expenses previously paid to the extent the class's net assets grow or expenses decline sufficiently to allow repayment without causing the class's operating expenses (after the repayment is taken into account) to exceed the lesser of: (1) the I Class Limit in place at the time such amounts were paid; or (2) the current I Class Limit. However, no repayment will be made more than three years after the date of a payment or waiver.

The Z Class is also subject to a contractual expense limitation agreement whereby Price Associates has agreed to waive and/or bear all of the Z Class' expenses (excluding interest; expenses related to borrowings, taxes, and brokerage; non-recurring, extraordinary expenses; and acquired fund fees and expenses) in their entirety. This fee waiver and/or expense reimbursement arrangement is expected to remain in place indefinitely, and the agreement may only be amended or terminated with approval by the fund's Board. Expenses of the fund waived/paid by the manager are not subject to later repayment by the fund.

Pursuant to these agreements, expenses were waived/paid by and/or repaid to Price Associates during the six months ended June 30, 2023 as indicated in the table below. At June 30, 2023, there were no amounts subject to repayment by the fund. Any repayment of expenses previously waived/paid by Price Associates during the period would be included in the net investment income and expense ratios presented on the accompanying Financial Highlights.

	Advisor Class	I Class	Z Class
Expense limitation/I Class Limit	1.24%	0.05%	0.00%
Expense limitation date	04/30/24	04/30/24	N/A
(Waived)/repaid during the period (\$000s)	\$—	\$—	\$(8,952)

In addition, the fund has entered into service agreements with Price Associates and two wholly owned subsidiaries of Price Associates, each an affiliate of the fund (collectively, Price). Price Associates provides certain accounting and administrative services to the fund. T. Rowe Price Services, Inc. provides shareholder and administrative services in its capacity as the fund's transfer and dividend-disbursing agent. T. Rowe Price Retirement Plan Services, Inc. provides subaccounting and recordkeeping services for certain retirement accounts invested in the Investor Class and Advisor Class. For the six months ended June 30, 2023, expenses incurred pursuant to these service agreements

were \$60,000 for Price Associates; \$952,000 for T. Rowe Price Services, Inc.; and \$275,000 for T. Rowe Price Retirement Plan Services, Inc. All amounts due to and due from Price, exclusive of investment management fees payable, are presented net on the accompanying Statement of Assets and Liabilities.

Mutual funds, trusts, and other accounts managed by Price Associates or its affiliates (collectively, Price Funds and accounts) may invest in the fund. No Price fund or account may invest for the purpose of exercising management or control over the fund. At June 30, 2023, approximately 100% of the Z Class's outstanding shares were held by Price Funds and accounts.

The fund may invest its cash reserves in certain open-end management investment companies managed by Price Associates and considered affiliates of the fund: the T. Rowe Price Government Reserve Fund or the T. Rowe Price Treasury Reserve Fund, organized as money market funds (together, the Price Reserve Funds). The Price Reserve Funds are offered as short-term investment options to mutual funds, trusts, and other accounts managed by Price Associates or its affiliates and are not available for direct purchase by members of the public. Cash collateral from securities lending, if any, is invested in the T. Rowe Price Government Reserve Fund. The Price Reserve Funds pay no investment management fees.

The fund may participate in securities purchase and sale transactions with other funds or accounts advised by Price Associates (cross trades), in accordance with procedures adopted by the fund's Board and Securities and Exchange Commission rules, which require, among other things, that such purchase and sale cross trades be effected at the independent current market price of the security. During the six months ended June 30, 2023, the fund had no purchases or sales cross trades with other funds or accounts advised by Price Associates.

Price Associates has voluntarily agreed to reimburse the fund from its own resources on a monthly basis for the cost of investment research embedded in the cost of the fund's securities trades and for the cost of brokerage commissions embedded in the cost of the fund's foreign currency transactions. These agreements may be rescinded at any time. For the six months ended June 30, 2023, these reimbursements amounted to \$510,000, which is included in Net realized gain (loss) on Securities in the Statement of Operations.

NOTE 7 - OTHER MATTERS

Unpredictable events such as environmental or natural disasters, war, terrorism, pandemics, outbreaks of infectious diseases, and similar public health threats may significantly affect the economy and the markets and issuers in which the fund invests. Certain events may cause instability across global markets, including reduced liquidity and disruptions in trading markets, while some events may affect certain geographic regions, countries, sectors, and industries more significantly than others, and exacerbate other pre-existing political, social, and economic risks.

Since 2020, a novel strain of coronavirus (COVID-19) has resulted in disruptions to global business activity and caused significant volatility and declines in global financial markets.

In February 2022, Russian forces entered Ukraine and commenced an armed conflict leading to economic sanctions being imposed on Russia and certain of its citizens, creating impacts on Russian-related stocks and debt and greater volatility in global markets.

In March 2023, the collapse of some US regional and global banks as well as overall concerns around the soundness and stability of the global banking sector has sparked concerns of a broader financial crisis impacting the overall global banking sector. In certain cases, government agencies have assumed control or otherwise intervened in the operations of certain banks due to liquidity and solvency concerns. The extent of impact of these events on the US and global markets is highly uncertain.

These are recent examples of global events which may have a negative impact on the values of certain portfolio holdings or the fund's overall performance. Management is actively monitoring the risks and financial impacts arising from these events.

INFORMATION ON PROXY VOTING POLICIES, PROCEDURES, AND RECORDS

A description of the policies and procedures used by T. Rowe Price funds to determine how to vote proxies relating to portfolio securities is available in each fund's Statement of Additional Information. You may request this document by calling 1-800-225-5132 or by accessing the SEC's website, sec.gov.

The description of our proxy voting policies and procedures is also available on our corporate website. To access it, please visit the following Web page:

https://www.troweprice.com/corporate/us/en/utility/policies.html

Scroll down to the section near the bottom of the page that says, "Proxy Voting Guidelines." Click on the links in the shaded box.

Each fund's most recent annual proxy voting record is available on our website and through the SEC's website. To access it through T. Rowe Price, visit the website location shown above, and scroll down to the section near the bottom of the page that says, "Proxy Voting Records." Click on the Proxy Voting Records link in the shaded box.

RESULTS OF PROXY VOTING

A Special Meeting of Shareholders was held on July 24, 2023 for shareholders of record on April 7, 2023, to elect the following director-nominees to serve on the Board of all Price Funds. The newly elected Directors took office effective July 24, 2023.

The results of the voting were as follows:

	Votes For	Votes Withheld
Melody Bianchetto	142,410,648	1,093,556
Mark J. Parrell	142,275,654	1,210,677
Kellye L. Walker	141,935,836	1,585,428
Eric L. Veiel	142,433,470	1,081,935

Teresa Bryce Bazemore, Bruce W. Duncan, Robert J. Gerrard, Jr., Paul F. McBride and David Oestreicher continue to serve as Directors on the Board of all Price Funds.

HOW TO OBTAIN QUARTERLY PORTFOLIO HOLDINGS

The fund files a complete schedule of portfolio holdings with the Securities and Exchange Commission (SEC) for the first and third quarters of each fiscal year as an exhibit to its reports on Form N-PORT. The fund's reports on Form N-PORT are available electronically on the SEC's website (sec.gov). In addition, most T. Rowe Price funds disclose their first and third fiscal quarter-end holdings on **troweprice.com**.

Each year, the fund's Board of Directors (Board) considers the continuation of the investment management agreement (Advisory Contract) between the fund and its investment adviser, T. Rowe Price Associates, Inc. (Adviser), as well as the investment subadvisory agreement (Subadvisory Contract) that the Adviser has entered into with T. Rowe Price Investment Management, Inc. (Subadviser), on behalf of the fund. In that regard, at a meeting held on March 6–7, 2023 (Meeting), the Board, including all of the fund's independent directors, approved the continuation of the fund's Advisory Contract and Subadvisory Contract. At the Meeting, the Board considered the factors and reached the conclusions described below relating to the selection of the Adviser and Subadviser and the approval of the Advisory Contract and Subadvisory Contract. The independent directors were assisted in their evaluation of the Advisory Contract and Subadvisory Contract by independent legal counsel from whom they received separate legal advice and with whom they met separately.

In providing information to the Board, the Adviser was guided by a detailed set of requests for information submitted by independent legal counsel on behalf of the independent directors. In considering and approving the continuation of the Advisory Contract and Subadvisory Contract, the Board considered the information it believed was relevant, including, but not limited to, the information discussed below. The Board considered not only the specific information presented in connection with the Meeting but also the knowledge gained over time through interaction with the Adviser and Subadviser about various topics. The Board also considered that the Subadviser has its own investment platform and investment management leadership, and the Adviser and Subadviser have implemented information barriers restricting the sharing of investment information and voting activity. The Board meets regularly and, at each of its meetings, covers an extensive agenda of topics and materials and considers factors that are relevant to its annual consideration of the renewal of the T. Rowe Price funds' advisory contracts, including performance and the services and support provided to the funds and their shareholders.

Services Provided by the Adviser and Subadviser

The Board considered the nature, quality, and extent of the services provided to the fund by the Adviser and Subadviser. These services included, but were not limited to, directing the fund's investments in accordance with its investment program and the overall management of the fund's portfolio, as well as a variety of related activities such as financial, investment operations, and administrative services; compliance; maintaining the fund's records and registrations; and shareholder communications. However, the Board noted that there are information barriers between investment personnel of the Adviser and Subadviser that restrict the sharing of certain information, such as investment research, trading, and proxy voting. The Board also reviewed the background and experience of the Adviser's and Subadviser's senior management teams and investment

personnel involved in the management of the fund, as well as the Adviser's compliance record. The Board concluded that the information it considered with respect to the nature, quality, and extent of the services provided by the Adviser and Subadviser, as well as the other factors considered at the Meeting, supported the Board's approval of the continuation of the Advisory Contract and Subadvisory Contract.

Investment Performance of the Fund

The Board took into account discussions with the Adviser and detailed reports that it regularly receives throughout the year on relative and absolute performance for the T. Rowe Price funds. In connection with the Meeting, the Board reviewed information provided by the Adviser that compared the fund's total returns, as well as a wide variety of other previously agreed-upon performance measures and market data, against relevant benchmark indexes and peer groups of funds with similar investment programs for various periods through December 31, 2022. Additionally, the Board reviewed the fund's relative performance information as of September 30, 2022, which ranked the returns of the fund's Investor Class for various periods against a universe of funds with similar investment programs selected by Broadridge, an independent provider of mutual fund data. In the course of its deliberations, the Board considered performance information provided throughout the year and in connection with the Advisory Contract review at the Meeting, as well as information provided during investment review meetings conducted with portfolio managers and senior investment personnel during the course of the year regarding the fund's performance. The Board also considered relevant factors, such as overall market conditions and trends that could adversely impact the fund's performance, length of the fund's performance track record, and how closely the fund's strategies align with its benchmarks and peer groups. The Board concluded that the information it considered with respect to the fund's performance, as well as the other factors considered at the Meeting, supported the Board's approval of the continuation of the Advisory Contract and Subadvisory Contract.

Costs, Benefits, Profits, and Economies of Scale

The Board reviewed detailed information regarding the revenues received by the Adviser under the Advisory Contract and other direct and indirect benefits that the Adviser (and its affiliates) may have realized from its relationship with the fund. In considering soft-dollar arrangements pursuant to which research may be received from broker-dealers that execute the fund's portfolio transactions, the Board noted that the Adviser bears the cost of research services for all client accounts that it advises, including the T. Rowe Price funds. The Board received information on the estimated costs incurred and profits realized by the Adviser from managing the T. Rowe Price funds. The Board also reviewed estimates of the profits realized from managing the fund in particular, and the Board concluded that the Adviser's profits were reasonable in light of the services provided to the fund.

The Board also considered whether the fund benefits under the fee levels set forth in the Advisory Contract or otherwise from any economies of scale realized by the Adviser. Under the Advisory Contract, the fund pays a fee to the Adviser for investment management services composed of two components—a group fee rate based on the combined average net assets of most of the T. Rowe Price funds (including the fund) that declines at certain asset levels and an individual fund fee rate based on the fund's average daily net assets—and the fund pays its own expenses of operations. Under the Subadvisory Contract, the Adviser may pay the Subadviser up to 60% of the advisory fees that the Adviser receives from the fund. The group fee rate decreases as total T. Rowe Price fund assets grow, which reduces the management fee rate for any fund that has a group fee component to its management fee, and reflects that certain resources utilized to operate the fund are shared with other T. Rowe Price funds thus allowing shareholders of those funds to share potential economies of scale. The fund's shareholders also benefit from potential economies of scale through a decline in certain operating expenses as the fund grows in size.

The fund also offers a Z Class, which serves as an underlying investment within certain T. Rowe Price fund of funds arrangements. The Adviser waives its advisory fee on the Z Class and waives or bears the Z Class's other operating expenses, with certain exceptions. The Board considered whether the advisory fee and operating expense waivers on the Z Class may present a means for cross-subsidization of the Z Class by other share classes of the fund. In that regard, the Board noted that the Z Class operating expenses are largely covered by the all-inclusive fees charged by the investing T. Rowe Price fund of funds and that any Z Class operating expenses not covered by the investing T. Rowe Price fund of funds' fees are paid by the Adviser and not by shareholders of any other share class of the fund.

In addition, the Board noted that the fund potentially shares in indirect economies of scale through the Adviser's ongoing investments in its business in support of the T. Rowe Price funds, including investments in trading systems, technology, and regulatory support enhancements, and the ability to possibly negotiate lower fee arrangements with third-party service providers. The Board concluded that the advisory fee structure for the fund provides for a reasonable sharing of benefits from any economies of scale with the fund's investors.

Fees and Expenses

The Board was provided with information regarding industry trends in management fees and expenses. Among other things, the Board reviewed data for peer groups that were compiled by Broadridge, which compared: (i) contractual management fees, actual management fees, nonmanagement expenses, and total expenses of the Investor Class of the fund with a group of competitor funds selected by Broadridge (Investor Class Expense Group); (ii) actual management fees and total expenses of the Advisor Class of the fund with a group of competitor funds selected by Broadridge (Advisor Class

Expense Group); and (iii) actual management fees, nonmanagement expenses, and total expenses of the Investor Class of the fund with a broader set of funds within the Lipper investment classification (Expense Universe). The Board considered the fund's contractual management fee rate, actual management fee rate (which reflects the management fees actually received from the fund by the Adviser after any applicable waivers, reductions, or reimbursements), operating expenses, and total expenses (which reflect the net total expense ratio of the fund after any waivers, reductions, or reimbursements) in comparison with the information for the Broadridge peer groups. Broadridge generally constructed the peer groups by seeking the most comparable funds based on similar investment classifications and objectives, expense structure, asset size, and operating components and attributes and ranked funds into quintiles, with the first quintile representing the funds with the lowest relative expenses and the fifth quintile representing the funds with the highest relative expenses. Broadridge constructed peer groups consisting of small-cap core funds, and the information provided to the Board indicated that the fund's contractual management fee ranked in the first quintile (Investor Class Expense Group), the fund's actual management fee rate ranked in the first quintile (Investor Class Expense Group and Expense Universe) and second quintile (Advisor Class Expense Group), and the fund's total expenses ranked in the first quintile (Investor Class Expense Group, Advisor Class Expense Group, and Expense Universe). At the request of the Adviser, Broadridge also constructed peer groups consisting of small-cap value funds, and the information provided to the Board indicated that the fund's contractual management fee ranked in the first quintile (Investor Class Expense Group), the fund's actual management fee rate ranked in the first quintile (Investor Class Expense Group, Advisor Class Expense Group, and Expense Universe), and the fund's total expenses ranked in the first quintile (Investor Class Expense Group, Advisor Class Expense Group, and Expense Universe).

The Board also reviewed the fee schedules for other investment portfolios with similar mandates that are advised or subadvised by the Adviser and its affiliates, including separately managed accounts for institutional and individual investors; subadvised funds; and other sponsored investment portfolios, including collective investment trusts and pooled vehicles organized and offered to investors outside the United States. Management provided the Board with information about the Adviser's responsibilities and services provided to subadvisory and other institutional account clients, including information about how the requirements and economics of the institutional business are fundamentally different from those of the proprietary mutual fund business. The Board considered information showing that the Adviser's mutual fund business is generally more complex from a business and compliance perspective than its institutional account business and considered various relevant factors, such as the broader scope of operations and oversight, more extensive shareholder communication infrastructure, greater asset flows, heightened business risks, and differences in applicable laws and regulations associated with the Adviser's proprietary mutual fund business. In assessing

the reasonableness of the fund's management fee rate, the Board considered the differences in the nature of the services required for the Adviser to manage its mutual fund business versus managing a discrete pool of assets as a subadviser to another institution's mutual fund or for an institutional account and that the Adviser generally performs significant additional services and assumes greater risk in managing the fund and other T. Rowe Price funds than it does for institutional account clients, including subadvised funds.

On the basis of the information provided and the factors considered, the Board concluded that the fees paid by the fund under the Advisory Contract are reasonable.

Approval of the Advisory Contract and Subadvisory Contract

As noted, the Board approved the continuation of the Advisory Contract and Subadvisory Contract. No single factor was considered in isolation or to be determinative to the decision. Rather, the Board concluded, in light of a weighting and balancing of all factors considered, that it was in the best interests of the fund and its shareholders for the Board to approve the continuation of the Advisory Contract and Subadvisory Contract (including the fees to be charged for services thereunder).















T.RowePrice®

100 East Pratt Street Baltimore, MD 21202

Call 1-800-225-5132 to request a prospectus or summary prospectus; each includes investment objectives, risks, fees, expenses, and other information that you should read and consider carefully before investing.